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ABSTRACT
Osteoporosis is a skeletal disorder characterized by compromised bone strength 
that predisposes to increased risk for fractures. Peak bone mass is an impor-
tant determinant of adult bone health and lifetime risk for fractures. Peak 
bone mass is mostly acquired by the age of 18 years, and therefore, childhood 
and adolescence are critical periods for bone mass gain. Long-lasting child-
hood disease may reduce the rate and/or magnitude of skeletal mass accrual; 
medications, especially glucocorticoids (GCs), chronic inflammation, decreased 
physical activity, hormonal deficiencies, delayed puberty, and poor nutrition 
may predispose these children and adolescents to impaired bone health. The 
improved long-term outcome of severe childhood diseases has increased the 
number of young patients at risk of skeletal complications. 
In this work, we studied overall bone health and the incidence and prevalence 
of fractures in children and adolescents treated for juvenile idiopathic arthri-
tis (JIA) or who had undergone solid organ transplantation (Tx). The clinical 
and treatment-related factors that predispose these patients to impaired bone 
health were assessed. The role of especially GCs and vitamin D in this process 
was evaluated.
The first study cohort included 62 patients diagnosed with JIA at least two 
years prior to the study and treated with GCs. The epidemiology of fractures 
after Tx was investigated in 196 patients and a more detailed analysis of bone 
health determinants was performed on 40 liver (LTx) and 106 renal transplan-
tation (RTx) patients. Clinical, biochemical, and treatment-related factors were 
evaluated. Bone mineral density (BMD) and vertebral morphology were as-
sessed by dual-energy X-ray absorptiometry. Standard radiographs were ob-
tained to detect vertebral fractures and to determine bone age; BMD values 
were adjusted for skeletal maturity.
Median BMD values were subnormal in all patient cohorts. The values were 
highest in patients with JIA (median for lumbar spine BMD Z-score -0.4) and 
lowest in patients with LTx (median Z-score -1.2). Age at transplantation influ-
enced BMD values in LTx but not RTx patients; BMD values were higher in pa-
tients who had LTx before the age of two years, while no difference was found 
in patients who had RTx before the age of two years and in those diagnosed 
at an older age. Further, BMD was lowest immediately after Tx, but tended to 
improve during follow-up despite long-term immunosuppressive medication. 
BMD Z-score decreased by ≥ 0.7 SD in 80% of LTx patients during puberty, and 
was significantly subnormal (mean LS Z-score -1.9) in all LTx patients at comple-
tion of puberty. However, the median BMD Z-scores increased in male RTx sub-
jects, while in females the trend was to decrease. The prevalence of vertebral 
fractures ranged from 10% to 19% in the cohorts. Most of the fractures were 
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asymptomatic and diagnosed only at screening. The prevalence of vertebral 
fractures was highest in adolescent LTx patients, and patients with fractures 
were older at the time of Tx (p = 0.002) and had more recently received the 
transplant (p = 0.019).
Vitamin D deficiency was common in all patient groups, and despite vitamin D 
substitution, only one-fourth of RTx and LTx patients achieved the target serum 
25-hydroxyvitamin D concentration of 80 nmol/L. Several potential risk factors 
for compromised bone health were identified in the cohorts, such as age of the 
patient at onset of JIA or Tx, time since Tx or JIA diagnosis, immunosuppressive 
drugs, and vitamin D and parathyroid hormone concentrations. However, none 
of these factors alone could be regarded as the main determinant of BMD or 
fractures. The total cumulative weight-adjusted dose of GC was not associated 
with BMD values in JIA or LTx patients. The combination of female gender and 
age over 15 years, parathyroid hormone concentration over 100 ng/L, and cu-
mulative weight-adjusted methylprednisolone dose over 150 mg/kg during the 
three preceding years were found to be important predictors for low lumbar 
spine BMD in RTx patients. 
Our study showed that impaired bone health, manifested as low BMD and 
increased fracture rate, is an important health concern in children with JIA, 
especially after solid organ transplantation. Special attention should be di-
rected to preventive measures during the immediate posttransplantation years 
and during adolescence since the skeleton seems to be most vulnerable dur-
ing these times. Vertebral fractures were common but often asymptomatic. As 
vertebral fractures are a sign of compromised bone quality, they should be ac-
tively screened and detected early. More attention should be paid to adequate 
calcium and vitamin D substitution in patients with JIA and after Tx. Careful 
follow-up is required to ensure optimal bone mass gain also in these children 
and adolescents. Further studies are warranted to evaluate optimal preventive 
measures and treatment modalities in pediatric patients with impaired bone 
health.
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1. INTRODUCTION
The basis of life-long bone health is formed in childhood and adolescence. In 
healthy children, bone mass increases during the two first decades of life, and 
a rapid increase in bone mass gain occurs during puberty (Bonjour et al. 1991, 
Kröger et al. 1993). An estimated 90% of peak bone mass (PBM) is acquired by 
the age of 18 years, and PBM is an important determinant of adult bone health 
(Bailey et al. 1999, Heaney et al. 2000). Chronic disease in childhood may inter-
fere with bone mass accrual, and genetically predetermined PBM might not be 
achieved. Inflammation, hormonal disturbances, delayed pubertal maturation, 
medications, especially glucocorticoids (GCs), impaired physical activity, and 
nutritional problems may predispose a child or adolescent to impaired bone 
health (Sochett and Mäkitie 2005, Bianchi 2007). 
Juvenile idiopathic arthritis (JIA) is the most commonly diagnosed rheumatic 
disease in children. The annual incidence of JIA in Finland is approximately 21 
per 100 000 children, and the prevalence in Scandinavia has been estimated to 
be 1 per 1000 children (Gare and Fasth 1992, Moe and Rygg 1998, Berntson et 
al. 2003). Solid organ transplantation (Tx) has become a successful treatment 
modality for children and adolescents with end-stage renal disease, terminal 
liver failure, metabolic disease, malignancy, and treatment-resistant heart fail-
ure. Outcomes of Tx have clearly improved during the last 20 years due to bet-
ter surgical techniques, advanced intensive care treatment, and developments 
in immunosuppressive therapy. The number of children and adolescents living 
with a graft is increasing. By February 2009, a total of 204 kidney, 96 liver, and 
59 heart transplantations had been performed in Finland on patients aged 
under 18 years.
Low bone mineral density (BMD) and fragility fractures are serious long-term 
complications associated with JIA (Varonos et al. 1987, Lien et al. 2003, Burnham 
et al. 2006a). The underlying renal or liver disease prior to Tx may itself have 
negative effects on the skeleton such that osteoporosis and fractures may be 
detected already at the time of Tx. Postoperatively, a further decline in BMD 
values has been reported (Feber et al. 1994, Guthery et al. 2003, Hardinger et 
al. 2003, Gasser 2008, Rodriguez-Garcia et al. 2009).
Preliminary data in children and adolescents with JIA or a history of Tx sug-
gest that these patients may be prone to impaired bone health and fractures. 
However, the prevalence and characteristics of impaired bone health as well as 
the contributing risk factors remain largely unknown. We therefore carried out 
this study to evaluate bone health characteristics and to determine specific risk 
factors for skeletal problems in patients with GC-treated JIA or solid organ Tx 
during childhood or adolescence.
INTRODUCTION
11
2. REVIEW OF THE LITERATURE
2.1 Bone structure
The skeleton, composed of bone and cartilage, gives mechanical support to the 
body and together with muscles, tendons, and joints facilitates locomotion. It 
also protects vital internal organs and bone marrow from potentially harm-
ful exogenous effects. The skeleton serves as a storage site for calcium, phos-
phate, and magnesium, and a buffering site for excess hydrogen ions (Demster 
2006).
Macroscopically, bone can be divided into two subtypes. Cortical or compact 
bone constitutes about 80% of the total skeleton and is mainly found in the 
diaphyseal parts of long bones. About 20% of the skeleton is trabecular bone, 
also called cancellous or spongy bone. This bone type is predominantly present 
in flat bones, vertebrae, and the metaphyseal and epiphyseal segments of long 
bones. The ratio of cortical and trabecular bone is 25:75 in the vertebrae and 
95:5 in the radial diaphysis (Clarke 2008). These bone types differ in metabolic 
activity. Trabecular bone is metabolically more active so that 25% of it is re-
placed annually, in contrast to only 2-5% of cortical bone. Cortical bone is very 
compact and mostly calcified, and its main function is mechanical and protec-
tive (Demster 2006). 
Bone is composed of mineral (50-70%), organic components (20-40%), water 
(5-10%), and lipids (<3%). Hydroxyapatite comprises 95% of the mineral com-
ponent, and the remainder consists mostly of calcium carbonate, magnesium, 
and citrate. The organic matrix is mainly composed of type 1 collagen (90%), 
with the remaining 10% consisting of noncollagenous proteins such as glyco-
proteins, osteocalcin, osteonectin, sialoprotein, osteopontin, and various pro-
teoglycans. Only 2% of the organic component of bone is composed of bone 
cells responsible for bone formation, resorption, and maintenance of the re-
modeling process (Demster 2006, Clarke 2008).




Osteoblasts are derived from bone marrow stromal cells or connective tissue 
mesenchymal cells that differentiate first into preosteoblasts and further into 
mature osteoblasts (Figure 1A). They are responsible for bone formation and 
synthesize and secrete collagen and matrix proteins. Cytokines and many hor-
mones regulate their activity. The osteoblasts synthesize osteoid, the organic 
bone matrix, and later take care of its mineralization. Their cytoplasms contain 
large amounts of alkaline phosphatase. Osteoblast lineage cells secrete osteo-
protegerin (OPG), an inhibitor of osteoclastogenesis, and have receptors for 
receptor activator of nuclear factor kappa B ligand (RANKL), 1,25-dihydroxy-
vitamin D [1,25(OH)2D], and parathyroid hormone (PTH), all of which can pro-
mote osteoclast activity and bone turnover. At the end of the secreting period, 
osteoblasts become calcified and lay in bone lacunae. Approximately 10-15% 
of osteoblasts are transformed later to osteocytes. Osteoblasts have tradition-
ally been thought to be the main target of PTH action in the skeleton (Harada 
and Rodan 2003, Aubin 2006). 
2.2.2 Osteocytes
Osteocytes are transformed from osteoblasts and account for over 90-95% of all 
bone cells in the skeleton (Figure 1A). They are thought to respond to mechani-
cal strain and transmit signals of bone formation and resorption (Bonewald 
and Johnson 2008). Osteocytes are found throughout the mineralized matrix, 
especially in cortical bone, but also in the trabecular bone. They are connected 
to each other and to surface osteoblasts via dendritic processes (Kamioka et al. 
2001). Unlike osteoblasts and osteoclasts, both of which have one specific func-
tion, osteocytes appear to be multifunctional. Remodeling is also suggested to 
be controlled by signals mediated by osteocytes, and osteocytes play an impor-
tant role in the repair of bone microdamages. Empty lacunae are observed in 
aging bone, and osteocytes are proposed to undergo apoptosis; bone loss may 
be partly due to osteocyte cell death (Bonewald 2004).
2.2.3 Osteoclasts 
Osteoclasts are derived from hematopoietic monocyte/macrophage precursor 
cells in the bone marrow and are responsible for bone resorption (Figure 1B). 
Cytokines, RANKL, and macrophage colony-stimulating factor are essential for 
basal osteoclastogenesis. 
REVIEW OF THE LITERATURE
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Monocytes circulate in blood and are attracted to the bone surface where they 
fuse to form osteoclasts. Osteoclasts secrete large quantities of matrix metal-
loproteinases and cathepsins, which are crucial for the removal of the bone’s 
organic matrix. Degradation products, such as collagen fragments, inorganic 
phosphate, and calcium, are processed within the osteoclasts and then released 
into the circulation (Teitelbaum 2000, Boyle et al. 2003).
Figure 1. Origin of osteoblasts, osteocytes (A ), and osteoclasts (B).
2.3 Bone modeling and remodeling
The shape and structure of bones are continuously modified and revised by 
two separate processes: modeling and remodeling. 
2.3.1 Modeling
Modeling refers to a process in which bones change their overall shape by the 
independent actions of osteoblasts and osteoclasts in response to physiologi-
cal stimuli or mechanical forces. This process maintains the normal shape of 
the tubular bones and results in an increase of the bone circumference during 
growth in children and adolescents. However, it occurs also in adults in re-
sponse to mechanical loads, to change the shape of the bone. In the modeling 
process, bone formation is independent of preceding bone resorption; osteo-
blasts are continuously active during the process, and therefore, rapid increases 
in the amount of bone tissue are possible. Osteoclasts remove less bone than is 
formed by osteoblasts, and this leads to a net increase in the amount of bone 
tissue (Demster 2006, Boyce and Xing 2008, Clarke 2008).
REVIEW OF THE LITERATURE
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2.3.2 Remodeling
Bone remodeling is a lifelong process consisting of successive cycles of bone 
resorption and formation that renew the bone while maintaining its structure 
(Figure 2). The regulation involves an interplay between systemic hormones, 
mechanical stimuli, and locally produced cytokines, growth factors, and other 
mediators (Compston 2001). Remodeling takes place in the basic bone multi-
cellular units along the trabecular surface and within the cortical bone. During 
a remodeling cycle osteoclasts remove a small quantity of bone, which is, af-
ter a reversal time, replaced by new tissue formed by osteoblasts (Boyce and 
Xing 2008). There is usually a balance between the removed and newly formed 
amounts of bone. In healthy young adults, the remodeling balance is close to 
zero such that the total amount of bone tissue remains largely unchanged. 
Bone loss occurs when the overall remodeling balance remains negative, and 
the amount of bone formed is less than the amount removed by bone resorp-
tion. The rate of bone remodeling and the number of bone multicellular units 
are increased in for example postmenopausal osteoporosis, hyperparathy-
roidism, and rheumatoid arthritis. The remodeling process is vital for the repair 
of microdamage and maintenance of skeletal integrity, but it does not result in 
changes in bone shape (Boyce and Xing 2008, Clarke 2008).
Figure 2. Bone remodeling cycle.
During the first phase, osteoclasts break down old bone matrix and a resorption 
cavity is formed. During the second phase, osteoblasts fill the cavity with colla-
gen and other matrix proteins. During the third phase, the collagenous matrix 
undergoes mineralization, and during the resting phase lining cells cover the bone 
surface.
REVIEW OF THE LITERATURE
15
2.3.3 OPG/RANKL/RANK system
RANKL is an essential cytokine for osteoclastogenesis. It is a member of the 
tumor necrosis factor (TNF) family and expressed by osteoblasts and their im-
mature precursors (Figure 3). Receptor activator of nuclear factor kappa B 
(RANK) is a receptor of RANKL and expressed by osteoclast lineage cells. It pro-
motes osteoclast formation and activation, and suppresses osteoclast apopto-
sis, thereby prolonging osteoclast survival time (Hofbauer and Schoppet 2004). 
OPG acts as a soluble decoy receptor for RANKL and is able to block its effects. 
Various tissues and cell types, including osteoblasts, produce OPG; it protects 
bone from excessive resorption by binding to RANKL. OPG-deficient mice dem-
onstrate decreased BMD, whereas the overexpression of OPG in transgenic 
mice leads to osteopetrosis (Bucay et al. 1998). Alterations in the OPG/RANKL/
RANK system are related to metabolic bone diseases in humans. Specific RANKL 
inhibitors, including a monoclonal antibody to RANKL, have been developed 
during the last few years. They have also been tested in humans in clinical trials 
showing successful inhibition of bone resorption, but the long-term effects are 
unknown and further studies are needed (Boyce and Xing 2008).
Figure 3. OPG-RANK-RANKL system.
REVIEW OF THE LITERATURE
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2.4. Bone mass accrual in childhood and adolescence
Skeletal mass increases from approximately 70-95 g at birth to 2400 and 3300 g 
in young women and men, respectively (Trotter and Hixon 1974). Childhood 
and adolescence are characterized by longitudinal growth, resulting from a 
combination of bone modeling and remodeling, as well as changes in skeletal 
shape and size. 
Mechanical forces on bone, generated by muscles, tightly control bone mass 
accrual (Frost and Schonau 2000). PBM is the amount of bone tissue accrued at 
the end of skeletal maturation (Bonjour et al. 1994). An estimated 70-80% of 
the variance in PBM between individuals is determined by genetic factors and 
the rest by environmental factors. These estimates are based on comparisons 
of BMD between monozygotic and dizygotic twins, and between twins and 
nontwin siblings (Dequeker et al. 1987, Pocock et al. 1987, Young et al. 1995, 
Eisman 1999, Albagha and Ralston 2003).
In healthy children, bone mass increases throughout the first two decades of 
life. However, the most rapid rise occurs during puberty in both genders, at 
11-13 years in girls and at 13-17 years in boys (Bonjour et al. 1991, Kröger et 
al. 1993). In girls, the rate of bone mass gain decreases rapidly after menarche, 
while in boys bone mass gain persists up to the age of 17 years (Theintz et al. 
1992). The timing of puberty may also be important for the magnitude of PBM. 
Late menarche in girls and delayed puberty in boys have in some studies been 
associated with reduced BMD (Rosenthal et al. 1989, Finkelstein et al. 1992, 
Bertelloni et al. 1995).
Before puberty, boys and girls develop bone mass at similar rates, but during 
puberty and early adulthood boys tend to acquire more bone mass (Nelson et 
al. 1997, Nguyen et al. 2001). Sex steroids are the key regulators of skeletal 
growth and maturation during puberty. In girls, estrogen initiates together 
with growth hormone (GH) and insulin-like growth factor 1 (IGF-1) the 3- to 
4-year pubertal growth spurt, during which the bone mass almost doubles. 
Estrogen is also required for the attainment of maximal PBM and is essential 
for normal closure of the growth plates in both genders (Compston 2001). The 
action of testosterone induces larger bone size and approximately 25% greater 
areal BMD (aBMD) in boys than in girls (Riggs et al. 2002). 
The PBM is known to be an important determinant of the future bone health 
and fracture risk; at least 90% of PBM is acquired by the age of 18 years (Bailey 
et al. 1999, Heaney et al. 2000). The full genetic potential of PBM is achieved 
only if physical activity, calcium and vitamin D intake, and nutrition are opti-
mized and growth and pubertal development occur normally. The impact of 
nonoptimal lifestyle factors may be most harmful during adolescence, the pe-
REVIEW OF THE LITERATURE
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riod during which the bone mass mostly accrues. A chronic illness may have del-
eterious effects on bone health by various mechanisms, including underlying 
illness, medications, associated secondary hypogonadism, and delayed puber-
tal maturation (Sochett and Mäkitie 2005, Bianchi 2007). These effects may be 
immediate, resulting in fragility fractures during childhood, or become evident 
with a delay after suboptimal attainment of PBM and subsequent susceptibility 
to adult osteoporosis.
2.5. Regulators of bone mass 
2.5.1 Calcium
The genetic potential of bone mass cannot be reached or maintained if cal-
cium supply from the diet or its absorption from the intestine is insufficient. 
During childhood and adolescence calcium is also needed for skeletal growth. 
Inadequate calcium intake results in low calcium absorption, lower circulat-
ing ionized calcium levels, and increased PTH secretion (Dawson-Hughes and 
Bischoff-Ferrari 2007). PTH regulates blood calcium levels by releasing calcium 
from bone and stimulating its reabsorption in the kidney, as well as by stimu-
lating the renal synthesis of 1,25(OH)2D, with a consequent increase in intes-
tinal calcium absorption. In addition to depleting or limiting bone mass gain, 
low calcium intake causes bone fragility through the PTH-stimulated increase 
in bone remodeling (Heaney et al. 2000). Calcium is a threshold nutrient so 
that below a certain level skeletal accumulation varies with intake, and above 
this level the accumulation is constant regardless of increased intake (Heaney 
2007). 
The dietary recommendations of the National Nutrition Council (2005) in 
Finland for daily calcium intake in children and adolescents are presented in 
Table 1.These recommended doses are below the threshold of calcium intakes 
suggested by Matkovic and Heaney (1992) and Jackman et al. (1997). A posi-
tive correlation between milk consumption in childhood and adolescence and 
BMD in adulthood has been observed (Murphy et al. 1994, Soroko et al. 1994, 
Teegarden et al. 1999). However, some studies in healthy children and adoles-
cents have found neither a correlation between total dietary calcium consump-
tion and childhood bone health nor consistent benefits from increased intake 
of dairy products for children’s bone health (Kröger et al. 1993, Kardinaal et al. 
1999, Jones et al. 2000). Other studies, by contrast, have reported these factors 
to have a positive effect (Ruiz et al. 1995, Goulding et al. 1998, Wang et al. 
2003). Courteix et al. (2005) showed that 800 mg calcium substitution increased 
the effect of physical exercise on bone mineral gain in prepubertal girls, but 
this effect was not seen in the group that was less active. In a placebo-control-
REVIEW OF THE LITERATURE
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led study of 51 premenarcheal twin pairs randomized to receive either 1200 
mg calcium substitution daily or placebo, a small increase in hip and lumbar 
spine BMD was found over the next 12-18 months, but these gains were not 
maintained at 24 months (Cameron et al. 2004).
2.5.2 Vitamin D 
Vitamin D metabolism 
Vitamin D2 or ergocalciferol is a plant or yeast-origin vitamin D, with wild 
mushrooms and algae being its main sources. Vitamin D2 is less potent and has 
a shorter duration of action than vitamin D3 (Armas et al. 2004). After sunlight 
exposure, ultraviolet B photons in humans penetrate the epidermis and pho-
tolyze 7-dehydrocholesterol into previtamin D3, which rapidly becomes a more 
thermodynamically stable molecule, vitamin D3 (Holick 2003). D3 or cholecalcif-
erol is obtained from such food items as fatty fish or fortified margarines and 
spreads. Increased skin pigmentation, use of sunscreens, and aging reduce the 
production of previtamin D3. 
Vitamin D3 is metabolized twice to be activated. First, it is hydroxylated in the liv-
er into 25-hydroxyvitamin D (25-OH-D) or calcidiol, which is the most abundant 
vitamin D metabolite in humans. The second hydroxylation, 1α-hydroxylation, 
occurs in the kidney, resulting in the synthesis of the active hormonal form of 
vitamin D, 1,25(OH)2D or calcitriol (Figure 4). Both calcidiol and calcitriol un-
dergo also 24-hydroxylation to form 24,25-dihydroxyvitamin D [24,25 (OH)2D] 
(Holick 2003, Lips 2006). 1,25(OH)2D is able to enter cells, bind to intracellular 
vitamin D receptor, and activate numerous target genes. The main effects of 
1,25 (OH)2D are to increase calcium absorption in the gut, maintain serum cal-
cium level within the normal range, and ensure normal bone mineralization. 











Table 1. Recommendation for calcium and vitamin D intake 
in children and adolescents according to the Finnish National 
Nutrition Council (2005).  
   
Age   Calcium (mg)        Vitamin D (μg)* 
     
6-11 months 540 10 
12-23 months 600 10 
2-5 years 600 7.5 
6-9 years 700 7.5 
10-17 years  900 7.5 
* 1 μg = 40 IU   
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Calcitriol influences not only calcium homeostasis and bone mineralization 
but has also antiproliferative effects, and vitamin D deficiency may play a role 
in the pathogenesis of autoimmune diseases (Holick 2007). Although most 
of the calcitriol production occurs in the proximal renal tubule, extrarenal 
1α-hydroxylase expression has been demonstrated in bone, vascular smooth 
muscle cells, brain, testis, prostate cells, colon epithelial cells, islet cells of the 
pancreas, macrophages, and parathyroid glands, and conversion of circulating 
25-OH-D to its active form occurs also in these tissues (Segersten et al. 2002, 
Somjen et al. 2005).
Figure 4. Metabolism of vitamin D (adapted from Deeb et al. 2007).
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Vitamin D deficiency
During childhood vitamin D deficiency causes rickets, which is characterized 
by failure or delay in endochondral ossification at long bone growth plates 
(Wharton and Bishop 2003). Rickets can manifest only prior to the fusion of 
the epiphysis, and thus, is a disease of childhood. Clinical symptoms include 
swollen growth plates in long bones, knock-knees or bowed legs, enlargement 
of the costochondral junctions of ribs, hypotonia, and delayed motor develop-
ment (Bishop 1999, Wharton and Bishop 2003). In adults, vitamin D deficiency 
induces osteomalacia, which is characterized by defective mineralization of os-
teoid on the cortical and trabecular surfaces of bone and an increased amount 
of unmineralized osteoid. Both rickets and osteomalacia may be associated 
with bone pain, muscle weakness, and hypocalcemic seizures. The typical labo-
ratory findings in vitamin D deficiency rickets/osteomalacia are hypocalcemia, 
normal or low phosphate, elevated PTH, and increased alkaline phosphatase
Serum 25-OH-D concentration reflects vitamin D status in the body. The half-
life of 25-OH-D is much longer than that of 1,25 (OH)2D, 14-21 days versus 4-6 
hours (Lauridsen et al. 2005). The target serum levels for optimal vitamin D 
status have increased during the last years. The S-25-OH-D threshold for maxi-
mal calcium absorption capacity is suggested to be 80 nmol/L, and this level has 
been regarded as the ideal minimum vitamin D concentration for optimal bone 
health (Heaney et al. 2003, Dawson-Hughes et al. 2005). The concentration of 
80 nmol/L has been shown to prevent bone loss, decrease fracture risk, and 
suppress PTH secretion in the elderly (Dawson-Hughes et al. 2005).
The daily recommendations for vitamin D intake in Finland, according to the 
National Nutrition Council (2005) are presented in Table 1. Healthy children and 
adolescents in Finland have been demonstrated to have poor vitamin D status, 
especially during wintertime. The vitamin D level was ≤ 37.5 nmol/L in 75% of 
171 healthy Finnish girls, aged 9-15 years during winter (Lehtonen-Veromaa 
et al. 2002). Välimäki et al. (2004) found that 39% of 220 healthy Finnish mili-
tary recruits had vitamin D values below 20 nmol/L in winter. Viljakainen et al. 
(2006) showed in a double-blind placebo-controlled study comprising 228 girls, 
aged 11-12 years, that vitamin D substitution of 5 μg and 10 μg increased bone 
mass accrual in the hip by 14.3% and 17.2%, respectively, compared with the 
placebo group. In the lumbar spine (LS), only the higher 10-μg dose increased 
bone mineral content significantly. It has been suggested that the recommen-
dations for daily vitamin D intake in Finland be re-evaluated since insufficient 
vitamin D status negatively impacts PBM accrual (Välimäki et al. 2004) and may 
even have negative effects on the extraskeleton.
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2.5.3 Physical activity
Bone mass accrual is tightly controlled by mechanical loads on bone gener-
ated by muscle forces (Frost and Schonau 2000). The beneficial effects of reg-
ular exercise on bone mass accrual during childhood and adolescence have 
been confirmed in many studies (Bailey et al. 1999, Nurmi-Lawton et al. 2004, 
Hasselstrom et al. 2007). The maximal positive effect on BMD may require 
quite intense loading with high impact forces. Weight-bearing exercise, such 
as walking, dancing, running, jogging, jumping, and aerobics, is considered 
most effective. The exact duration or intensity of physical activity that provides 
the optimal stimulus for bone mass accrual is unclear. In one study, gymnasts 
had higher spinal and femoral BMD compared with swimmers or sedentary 
girls (Courteix et al. 1998). Differences in BMD values between the dominant 
and nondominant arm in junior tennis players were found, and if the training 
program was started already in childhood, also the diameter of the dominant 
forearm was increased (Haapasalo et al. 1998). Whether the positive effects 
of physical activity on the growing skeleton are maintained during adulthood 
remains to be elucidated. Baxter-Jones et al. (2008) found that physically active 
adolescents, as compared with their less active peers, maintained their higher 
bone mineral content (BMC) into the third decade of life. In a Japanese study, 
46 postmenopausal women who had participated in weight-bearing sports be-
tween 12-18 years had significantly greater BMC in the lumbar spine and femo-
ral neck and also greater femoral diaphyseal bone cross-sectional area than 
their less active peers (Kato et al. 2009). Impaired physical activity is common in 
chronically ill children and may negatively affect their BMD.
2.5.4 Estrogen, testosterone, and growth hormone 
The period prior to puberty bone growth is largely GH-dependent, but sex ster-
oids are essential for the completion of epiphyseal maturation and bone min-
eral increase during puberty. Trabecular bone is influenced more than cortical 
bone by sex steroids (Bass et al. 1999). Patients with hypogonadism have re-
duced BMD and increased fracture risk, and hormonal replacement therapy is 
associated with BMD improvement (Saggese et al. 1997). Boys with aromatase 
deficiency or estrogen receptor defects have low BMD (Khosla et al. 2002), 
confirming the significant role of estrogen also in boys for normal bone mass 
accrual. Secondary hypogonadism and delayed pubertal maturation may be 
associated with a chronic illness and predispose to osteoporosis.
GH deficiency in children and adolescents is associated with decreased bone 
mass gain and low BMD (Baroncelli et al. 2000). Adequate GH treatment leads 
to increased bone mass (Boot et al. 1997, Baroncelli and Saggese 2005). The GH 
action on bone is mediated mainly through IGF-1, which positively affects the 
osteoblasts and stimulates the synthesis of collagen. In GH-deficient children 
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and adolescents, low bone mass is partly due to reduced bone size and delayed 
skeletal maturation. 
2.5.5 Parathyroid hormone
PTH is an 84-amino-acid peptide released from the parathyroid glands in re-
sponse to hypocalcemia. Its main function is to maintain a constant plasma 
ionized calcium concentration. A reduction in plasma calcium increases PTH se-
cretion, while low phosphate or elevated calcium decreases it. The three physi-
ological regulators of PTH secretion and synthesis are extracellular calcium and 
phosphate ions and calcitriol. In bone, PTH stimulates calcium and phosphate 
release, and in the kidney tubulus it stimulates reabsorption of calcium and 
exretion of phosphate. It also enhances renal synthesis of 1,25 (OH)2D, thereby 
increasing calcium and phosphate absorption from the gut (Brown 2006).
The action of PTH on bone is dual: stimulation or inhibition of bone collagen 
and synthesis of matrix. Chronic administration or increased secretion of PTH in 
primary hyperparathyroidism leads to a catabolic state, which stimulates bone 
resorption and leads to bone loss. The release of calcium is accompanied by the 
release of phosphate and matrix components. Paradoxically, when PTH is ad-
ministered intermittently in suitable doses, it increases the volume of trabecu-
lar bone. These anabolic effects of PTH are under intensive research to develop 
new protocols for osteoporosis treatment and prevention (Potts 2005). A re-
combinant human PTH (1-34, teriparatide), given subcutaneously, was found 
to reduce the number of new vertebral fractures by 65% in postmenopausal 
women (Neer et al. 2001). The use of teriparatide is contraindicated in children 
because of the potential risk of osteosarcoma.
In the kidney, PTH inhibits phosphate reabsorption in both the proximal and 
distal tubules, while calcium reabsoption is increased only in the distal tubulus. 
In patients with normal kidney function, PTH induces phosphate excretion in 
urine, which can lead to hypophosphatemia and stimulate bone resorption 
(Brown 2006).
In chronic renal failure, several factors may contribute to the development 
of secondary hyperparathyroidism: 1) impaired phosphate elimination in the 
kidneys, 2) hypocalcemia, 3) impaired 1,25 (OH)2D synthesis, and 4) decreased 
number of calcium-sensing and vitamin D receptors in the parathyroid glands. 
In secondary hyperparathyroidism, PTH excretion is increased at all plasma 
calcium levels (Wesseling et al. 2008). Chronic kidney disease (CKD)-mineral 
bone disorder occurs in patients with chronic renal failure and who have 1) 
alterations in calcium, phosphate, and vitamin D metabolism, 2) abnormali-
ties in bone turnover, mineralization, and volume, or 3) extraskeletal calcifica-
tion (Sanchez 2008). The term renal osteodystrophy defines alterations in bone 
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morphology associated with CKD. Histomorphometry allows assessment of the 
state of bone turnover, mineralization, and bone volume (Moe et al. 2006).
2.6 Osteoporosis
2.6.1 Definition of osteoporosis
The World Health Organization (WHO) has defined osteoporosis as a skeletal 
disorder characterized by low bone mass and micro-architectural deterioration 
of bone tissue with a consequent increase in bone fragility and susceptibil-
ity to fracture (WHO 1994). A redefinition was published in 2000 by National 
Institutes of Health (NIH), in which osteoporosis was defined as a skeletal disor-
der characterized by compromised bone strength, predisposing to an increased 
risk of fracture (NIH 2000). In clinical practice, the diagnosis of osteoporosis 
in adults is often based only on the assessment of BMD by dual-energy X-ray 
absorptiometry (DXA), without previous fractures. BMD results are presented 
as T-scores: the measured BMD is compared with the average BMD of young 
adults at the time of PBM, and the difference is presented in standard devia-
tion (SD) units. These T-scores are used to define osteoporosis and osteopenia. 
Osteoporosis is defined as a T-score less than or equal to -2.5, and osteopenia 
as a T-score between -1.0 and -2.5. A T-score less than or equal to -2.5 in con-
junction with a history of low-impact fracture is considered severe osteoporosis 
(WHO 1994). 
For children and adolescents who have not yet achieved their PBM, the use of 
T-score is not possible. Instead, the use of Z-scores is recommended. A Z-score is 
a comparison of the measured BMD with the mean BMD for gender and age in 
SDs. According to a position statement of the International Society for Clinical 
Densitometry (Rauch et al. 2008), the diagnosis of osteoporosis in children and 
adolescents should not be based on DXA results alone, but requires both a sig-
nificant fracture history and a low BMC or BMD. A clinically significant fracture 
history is defined as a vertebral compression fracture, one lower extremity long 
bone fracture, or two or more upper extremity long bone fractures. Low BMC 
or aBMD is defined as a Z-score ≤ -2.0, adjusted for age, gender, and/or body 
size, as appropriate. A Z-score between -2.0 and -1.0 is defined as low-normal. 
For children and adolescents, the term “low BMD for chronological age” may 
be used if the subject’s Z-score is below -2.0, stature is normal for age, and no 
fracture history is present.
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2.6.2 Classification of osteoporosis
Primary osteoporosis
Osteoporosis in an otherwise healthy child is defined as primary and is divided 
into heritable disorders of connective tissue and idiopathic juvenile osteoporosis. 
Genetic defects influencing bone development, such as osteogenesis imperfecta 
(OI), Ehlers-Danlos syndrome, Marfan syndrome, osteoporosis-pseudoglioma 
syndrome, and homocystinuria, are the major causes of primary osteoporosis. In 
idiopathic juvenile osteoporosis, the underlying defect is unknown. 
OI is the most common form of primary osteoporosis. OI is characterized by bone 
fragility and low bone mass. Mutations in the type I collagen genes (COL1A1 or 
COL1A2) cause most of the seven different clinical subtypes (Rauch and Glorieux 
2004, Glorieux 2008). However, new mutations in for example, P3H1 and CRTAP 
genes have recently been found in rarer forms of OI (Cheung and Glorieux 2008). 
The severity of the disease varies widely; the most severe forms lead to perinatal 
death, while patients with the mildest form may even avoid fractures. The ex-
traskeletal manifestations include blue sclerae, dentinogenesis imperfecta, skin 
hyperlaxity, hearing impairment, and hypermobility of the joints, but their ab-
sence does not exclude the diagnosis.
Idiopathic juvenile osteoporosis is a rare condition described by Dent and 
Fieldman (1965) over four decades ago with an estimated incidence of 1:100 
000. It usually presents during pre-pubertal years (mostly between 8 and 12 years 
of age) with back pain, walking difficulties, and vertebral compression fractures 
in an otherwise healthy child or adolescent. It is also characterized radiologically 
by radiolucent areas in the metaphyses of long bones. The clinical course of this 
disease is variable and spontaneous improvement has been reported in most pa-
tients, but in others rapid progression may occur (Dent 1977). The genetic cause 
is in most cases unknown, but in a study by Hartikka et al. (2005) 3 of 20 patients 
with idiopathic juvenile osteoporosis had a heterozygous mutation in the low-
density lipoprotein receptor-related protein 5 (LRP5) gene.
Secondary osteoporosis
Osteoporosis caused by an underlying illness and/or its treatment is defined as 
secondary. The list of causes of secondary osteoporosis in children is growing, 
due in part to improved long-term outcomes for children with chronic diseases. 
In addition to the chronic illness itself, several other factors, such as medica-
tions, chronic inflammation, impaired physical activity, hormonal causes, or 
nutritional problems, may predispose these patients to impaired bone health. 
The illnesses that may be associated with secondary osteoporosis and possible 
predisposing factors in these patient groups are shown in Table 2.
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2.7 Juvenile idiopathic arthritis and bone health
In previous studies, JIA has been associated with osteoporosis, vertebral and 
peripheral fractures, and growth retardation (Elsasser et al. 1982, Varonos et 
al.1987, Simon et al. 2002, Wang et al. 2002, Celiker et al. 2003, Lien et al. 2003, 
Burnham et al. 2006a). One longitudinal study followed 63 children with JIA 
and healthy controls for 18 months. Nine of the patients had a vertebral frac-
ture (VFx) at baseline and four experienced one during the follow-up (Elsasser 
et al. 1982). In a population-based study of 1939 patients with childhood-onset 
arthritis and 207 072 controls, the patients with arthritis had an increased risk 
of both vertebral and nonvertebral fractures, especially during adolescence 
and after the age of 45 years (Burnham et al. 2006a). A Norwegian study of 
105 adolescent patients with JIA found aBMD Z-score below -1.0 in 25%, 34%, 
and 31% of patients for the LS, whole body, and femoral neck, respectively. 
Low aBMD values were more frequent in adolescents with early-onset JIA than 
in young adult patients with later-onset JIA. Of all patients, 71% had never 
been on GC treatment, but 39% of this group had low BMD values (Lien et al. 
2003).
2.8 Bone health in patients with a history of solid organ 
transplantation
Several studies have evaluated bone health in adult Tx patients and reported 
osteoporosis and fragility fractures. A high prevalence of osteoporosis (T-score 
≤ -2.0) for the LS and/or hip was found in 41% of 32 adults after heart trans-
plantation (HTx) (Glendenning et al. 1999). Leidig-Bruckner et al. (2001) re-
ported that nearly one-third of 105 patients had sustained a vertebral fracture 
(VF) by the end of the third year after HTx. Reduced BMD and VF after LTx are 
prevalent in adults (Ramsey-Goldman et al. 1999, Hamburg et al. 2000, Ninkovic 
et al. 2000, Leidig-Bruckner et al. 2001, Hardinger et al. 2003). Longitudinal 
BMD measurements showed the greatest reduction in the LS during the first six 
months postoperatively (Hardinger et al. 2003). Long-term follow-up (up to 15 
years) demonstrated an improvement in BMD mainly during the second year 
post-LTx, with no deterioration thereafter (Hamburg et al. 2000). One study 
found VFx in 14% of 130 LTx patients in the first postoperative year, and the 
proportion increased to 21% by the end of the second year (Leidig-Bruckner 
et al. 2001). Most of the fractures occurred in the lower thoracic or lumbar re-
gion. The patients with a LS BMD T-score below -2.5 were at increased risk for 
VFx (Leidig-Bruckner et al. 2001). In adult RTx patients, previous studies have 
reported variable prevalence rates of osteoporosis and fractures. In a cross-
sectional study in adults, the prevalence of osteoporosis was 53% (Durieux et 
al. 2002). One study revealed no bone loss after the second posttransplanta-
tion year, while another study found progressive improvement in postopera-
tive BMD, approaching normal values after 10 years (Grotz et al. 1995, Carlini 
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et al. 2000). A nearly 5-fold increase in fracture incidence was reported in adult 
RTx patients and the frequency of VFx was over 20-fold higher as than that of 
the general population (Abbott et al. 2001, Vautour et al. 2004).
Data on BMD development, especially VFx in pediatric liver transplant recipi-
ents, are limited (Hill et al. 1995, Guthery et al. 2003). In a study by Hill et al. 
(1995), 19 (16%) of 117 children who underwent LTx sustained a total of 69 
fractures in a six-year period. Forty-nine (71%) of the fractures in 13 children 
occurred before Tx, and 20 fractures (29%) in six patients occurred after Tx. 
Almost all of the fractures occurred in the ribs or long bones, no spinal radio-
graphs were taken, and no VFx, were detected (Hill et al. 1995). In another 
study of 109 pediatric long-term LTx survivors, only 7% had reduced bone mass 
(LS BMD Z-score < -2.0). These patients had been treated for rejection at least 
once and had greater cumulative prednisone exposure during the preceding 
year than those without reduced bone mass. No fracture assessment was in-
cluded in this study (Guthery et al. 2003).
Limited data on bone health implications of pediatric RTx are available. Most 
of the previous studies are cross-sectional BMD evaluations lacking informa-
tion on fractures. Chesney et al. (1984) published the first paper on children’s 
bone health outcome after RTx and reported a significant decrease of BMC in 
11 of their 18 patients; the loss was significantly greater in patients receiving 
daily GC treatment than in those on alternate-day dosing. In a cross-sectional 
study of 83 children and adolescents receiving living-related RTx, the LS aBMD 
Z-score was between -1.0 and -2.5 in half of the patients and below -2.5 in 
one-fifth (el-Husseini et al. 2004). In another cross-sectional study, the LS BMD 
Z-score was below -2.0 in 45% of the 33 children; older age and longer time 
since RTx increased the risk for low BMD (Ellis et al. 2000). Feber et al. (1994) 
found in a longitudinal study of 14 children a significant decrease in BMD dur-
ing the first six months postoperatively despite normal graft function. During 
the following 18 months the bone loss stabilized and BMD increased.
2.9 Dual-energy X-ray absorptiometry
The first DXA scanners were introduced in the late 1980s to detect postmeno-
pausal osteoporosis. Nowadays, however, DXA measurements are increasingly 
performed also on children and adolescents with chronic disease or frequent 
fractures. Measurement sites generally used in clinical practice for adults are LS 
(from L1 or L2 to L4), femoral neck, and total hip (Kanis 2000). 
DXA is a projectional technique that provides a two-dimensional measurement 
of BMC (g) and bone area (cm²) of three-dimensional bone. BMD (cm²), derived 
from equation BMC/bone area, is not the true volumetric density (g/cm³) be-
cause no measure of bone depth is included. Therefore, children with smaller 
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bones will falsely establish lower aBMD than children with larger bones, de-
spite identical volumetric bone densities because bone thickness is not meas-
ured. Further, DXA is unable to distinguish between trabecular and cortical 
bones (Leonard 2005).
According to the International Society for Clinical Densitometry Official 
Positions 2007, the pediatric DXA examination should ideally include scans of 
the LS (posterior-anterior) and the total body less the head (Gordon et al. 2008). 
The hip, including total hip and proximal femur, is not regarded as a reliable 
measurement site in growing children due to a significant variability in skel-
etal development and lack of reproducible regions of interest. The whole body 
measurement gives important data of the total bone mass and body composi-
tion and provides also data of the fat mass and lean (mainly muscle) body mass 
separately. A high correlation between muscle mass and bone mass in children 
is in line with the functional bone-muscle unit theory (Högler et al. 2003). BMC 
is thought to be one of the preferred methods of bone status assessment be-
cause of its reproducibility and lack of errors related to areal density measure-
ments. However, the lack of reference values for children under nine years of 
age limits its use in children (Ellis et al. 2001, Kalkwarf et al. 2007). In primary or 
secondary hyperparathyroidism, in which cortical bone loss prevails, a forearm 
measurement may give more information, but scant pediatric reference data 
exist for the forearm. With short imaging time and low radiation dose, DXA is 
also easily performed on small children. 
Bone age corresponds to pubertal maturation. Children with a chronic disease 
often have delayed pubertal development, and correction of the DXA result 
for bone age is important to avoid falsely low values. Also correction for height 
age is used to avoid the impact of short stature on the results. Height age is es-
timated by determining the age at which the fiftieth percentile on the height-
for-age growth curve corresponds to the child’s height. Correction for height 
age is problematic if a short but already pubertal adolescent is compared with 
a prepubertal child (Bachrach 2005). 
Vertebral fracture assessment (VFA) or instant vertebral assessment (IVA) of 
the thoracic and LS, usually from T4 to L5, can also be obtained by some DXA 
instruments using a specific software with the patient in either the supine or 
lateral position (Figure 5). The radiation exposure is very low (from 0.11 μSv 
to 14.9 μSv depending on the device used) compared with conventional radi-
ography and is therefore ideal, especially for children. Whether the resolution 
of VFA is adequate for analysis of vertebral morphology is unclear. Studies in 
adult patients have demonstrated that the sensitivity and specificity of IVA 
were comparable with those of spine radiographs in detecting grade 2 or 3 ver-
tebral fractures, but not as good in lower grade fractures (Lewiecki and Laster 
2006). In detecting morphological vertebral deformities, VFA has been shown 
to be accurate in adults in the lower thoracic and lumbar regions (Chapurlat et 
REVIEW OF THE LITERATURE
29
al. 2006, Damiano et al. 2006). There is only one pediatric study comparing IVA 
with conventional radiographs, and it found good visibility of vertebrae in T8-
L4, but compromised visibility in the upper thoracic region (T4-Th7); IVA was 
constantly inferior to standard radiographs. Only 9 (36%) of the 25 vertebral 
fractures found in plain radiographs were detected in IVA images (Mäyranpää 
et al. 2007). 
Strong evidence exists that, in adults, the BMD value is a good predictor for 
future fracture risk. Marshall et al. (1996) found that the risk of fracture dou-
bles with each 1 SD unit decrease in aBMD T-score. In children and adolescents, 
the relationship between BMD and fracture risk is not yet clear. Some studies 
have suggested that healthy children prone to developing osteoporosis and 
fractures later in life could be identifi ed by measuring BMD before pubertal 
development occurs (Ferrari et al. 1998, Flynn et al. 2007). Skaggs et al. (2001) 
found in 100 healthy girls, aged 4-15 years, half of whom had sustained a fore-
arm fracture, that the peripheral quantitative computed tomography meas-
ured cross-sectional area at the distal radius was 8% smaller in the fracture 
group (Skaggs et al. 2001). Goulding et al. (2000) measured the aBMD values of 
100 girls, 3-15 years of age, after a forearm fracture and noted that those who 
sustained a new fracture during four-year follow-up had signifi cantly lower 
total body aBMD at baseline.
Figure 5. Vertebral fracture assessment by DXA, the red arrow on the left
shows a compression fracture. Lumbar spine aBMD development with
age is shown on the right.
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2.10 Skeletal effects of immunosuppressive drugs
2.10.1 Glucocorticoids
Almost 80 years ago, Harvey Cushing (1932) observed that patients with excess 
endogenous glucocorticoid (GC) developed bone fractures. Synthetic GCs have 
been widely used in juvenile idiopathic arthritis (JIA) and after organ trans-
plantations because of their anti-inflammatory and immunosuppressive po-
tential. However, similarly to endogenous GC excess, they are known to have 
a strong negative influence on bone metabolism, even when administered in 
low doses. 
GCs have both direct and indirect effects on the skeleton and cause increased 
bone resorption and decreased bone formation. These changes have been con-
firmed also histologically in bone biopsies (Dalle Carbonare et al. 2001). The 
skeletal effects of GCs occur in two phases. Increased bone resorption appears 
initially and may be due to indirect effects of GCs, including decreased intes-
tinal calcium absorption, increased urinary calcium excretion, and decreased 
synthesis of gonadotrophins, sex steroids, and IGF-1. After extended exposure 
to GCs, the function of osteoblasts decreases and bone formation is impaired 
(Canalis 2003, Canalis et al. 2007). GCs increase RANKL expression, inhibit OPG 
production by osteoblasts, and suppress OPG serum levels (Hofbauer et al. 
1999, Sasaki et al. 2001). GCs induce apoptosis of mature osteoblasts and os-
teocytes, resulting in a reduced number of bone-forming cells (Weinstein et al. 
1998). The impact of GCs on bone is summarized in Table 3 and Figure 6.
 
Table 3. Mechanisms of glucocorticoid-  
induced bone loss.   
Indirect effects  
intestinal calcium absorption  
urinary calcium excretion  
gonadotrophin synthesis  
sex steroid synthesis  
IGF-1 synthesis  
Direct effects  
osteoclastogenesis  
apoptosis of osteoblasts and osteocytes  
RANKL expression  
osteoblast life span  
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Apoptosis of osteocytes may play an important role in GC-related BMD loss, 
microarchitectural deterioration of bone structure, and predisposition to frac-
tures. Osteocytes are believed to sense the need for remodeling and communi-
cate with lining cells (Manolagas 2000). The negative effect on bone formation 
leads to a reduced total amount of bone replaced in each remodeling cycle 
(Dalle Carbonare et al. 2005). Numerous studies in adults and animal models 
have demonstrated that GCs induce predominantly trabecular bone loss (Dalle 
Carbonare et al. 2001). GC-induced myopathy may also contribute to bone loss 
by altering gravitational forces on the skeleton and reducing weight-bearing 
activities and mobility. Secondary hyperparathyroidism does not explain GC-
induced osteoporosis because in most patients PTH is normal or only slightly 
elevated, and GCs mainly induce trabecular bone loss whereas hyperparathy-
roidism is predominantly associated with cortical bone loss (Canalis et al. 2007). 
In children and adolescents, impaired linear growth is associated with GC ther-
apy (Foster et al. 2004). GCs and IGF-1 have opposite effects on the skeleton; 
IGF-1 increases the function of osteoblasts, bone collagen synthesis, and bone 
formation (Giustina et al. 2008).
Figure 6. Glucocorticoids and bone.
GC-induced osteoporosis is the most common form of secondary osteoporosis 
(Mazziotti et al. 2006). The risk of fractures is increased in adult patients during 
the use of GCs (van Staa et al. 2000a, Kanis et al. 2004, Steinbuch et al. 2004). 
Decreased BMD has been described in many pediatric disorders treated with 
GCs, but much less is known about fractures and GC use in this population. A 
large population-based study reported that children who required more than 
four courses of oral GCs had an increased risk of fractures, especially in the 
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forearm, but the risk decreased and was comparable with that of nonusers 
after cessation of treatment (van Staa et al. 2003a). In adults, the fracture risk 
was increased mostly in the hip and spine (van Staa et al. 2000b). 
The disease for which GC treatment is used may also contribute to the increased 
risk. Inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), also 
suppress bone formation and induce bone loss. Independent of GC therapy, 
increased fracture risk has been reported in adults with rheumatoid arthritis 
or inflammatory bowel disease (Cooper et al. 1995, van Staa et al. 2003b). The 
largest adult study, including over 200 000 GC users and their age- and sex-
matched controls, reported that the risk of fractures was related primarily to 
daily rather than cumulative GC dose, so that daily doses > 2.5 mg prednisone 
equivalents were associated with an increased risk for both vertebral and hip 
fractures (Van Staa et al. 2000a) Osteonecrosis, also known as avascular necro-
sis, is a serious complication of GC use. It occurs most often in the proximal 
femur, the head of the humerus, and the distal femur. The etiology remains un-
known, but may be due to fat emboli, oxidation injury, or enhanced osteocyte 
apoptosis (Mankin 1992, Weinstein et al. 2000, Ichiseki et al. 2005).
An alternate-day steroid regimen may induce less GC side-effects than the daily 
regimen (Jabs et al. 1996, Hiraoka et al. 2003, Vidhun and Sarwal 2005). In ad-
dition to dosing, other factors, such as individual variability in the response to 
oral GC therapy, are important and partly explain why some patients seem to 
be more sensitive to GC-induced obesity, metabolic changes, osteoporosis, and 
fractures. Genetic polymorphisms in the GC and other steroid hormone recep-
tor genes are associated with differences in BMD development and alterations 
in body composition after GC exposure (Gennari et al. 2002, van Rossum and 
Lamberts 2004). It has also been suggested that individual variability in expres-
sion of GC-metabolizing enzymes in osteoblasts may result  in higher GC expo-
sure within bone and development of localized osteoporosis (Cooper 2004).
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2.10.2 Other immunosuppressive drugs
Cyclosporine A (CsA) and tacrolimus (FK506) are calcineurin inhibitors that sup-
press the activation and production of T-cells and the release of interleukin-2 
and other cytokines (Matsuda et al. 2000). In murine models, CsA administration 
causes high-turnover osteoporosis, mainly in trabecular bone, and increases os-
teocalcin and 1,25 (OH)2D levels. In a high-turnover state, both bone resorption 
and formation are increased, but resorption rate exceeds bone formation. In 
a rodent model, the actions of FK506 were similar to those of CsA (Movsowitz 
et al. 1989, Epstein 1996). The effects of calcineurin inhibitors on the human 
skeleton are difficult to study because these inhibitors are rarely used in isola-
tion and usually treated patients have an underlying disease that may itself 
affect bone health. Comparison of CsA monotherapy with a non-CsA regimen 
in renal transplant patients showed that both regimens decreased BMD at the 
distal radius and less in the LS but no statistical difference in the amount of 
bone loss was found between the groups (Cueto-Manzano et al. 2003). Kidney 
transplant patients receiving CsA had more bone loss than patients on FK506 
(Josephson et al. 2004). FK506-based regimens may improve bone health by al-
lowing the use of lower GC doses. Chronic nephrotoxicity leading to secondary 
renal insufficiency is occasionally a problem in patients treated with calcineurin 
inhibitors and may predispose to renal osteodystrophy (Campbell et al. 2006).
Mycophenolate mofetil (MMF), azathioprine (Aza), or rapamycin do not ap-
pear to have significant skeletal side-effects (Bryer et al. 1995, Romero et al. 
1995, Dissanayake et al. 1998). Methotrexate (MTX) has been reported to cause 
osteopenia when used to treat childhood malignancies (Mandel et al. 2004). 
The dosing in JIA is substantially lower and does not seem to have adverse ef-
fects on bone (Cranney et al. 2001, Cimaz 2002). TNF-α is known to be an im-
portant mediator in various inflammatory conditions and in postmenopausal 
osteoporosis (Feng 2005). The new anti-TNF agents, introduced at the end of 
1980s for the treatment of rheumatic diseases in adults and approximately ten 
years later also in children, may prevent bone loss by regulating osteoclast 
formation and activation or by decreasing the amount of circulating cytokines 
(Saidenberg-Kermanac’h et al. 2004, Feng 2005). 
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3. AIMS OF THE STUDY
Children with JIA or a history of solid organ Tx have several potential risk fac-
tors for osteoporosis. However, the prevalence of osteoporosis and fragility 
fractures, and the role of specific clinical and treatment-related risk factors in 
the development of osteoporosis remain largely unknown. We therefore car-
ried out a study in children with JIA and in children with an organ transplant. 
Specific aims were as follows:
 1. To investigate the incidence and prevalence of fractures in children  
  and adolescents with JIA or a solid organ transplant
 
 2. To assess BMD by DXA
 3. To determine the role of GC exposure and vitamin D deficiency in the  
  development of impaired bone health
 4. To identify other clinical and treatment-related factors that may 
  predispose to poor bone health
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4. MATERIALS AND METHODS
4.1 Patients and controls
The studies of this thesis comprised 62 patients with GC-treated JIA (Study I), 
196 patients with a history of solid organ transplantation during childhood or 
adolescence (Study II), 40 pediatric LTx patients (Study III), and 106 pediatric 
RTx recipients (Study IV). Twenty-five and 68 of the patients in Studies III and 
IV, respectively, were also included in Study II.
In epidemiological Study II, fractures in children, adolescents, and young adults 
(from 0 to 30 years) that were treated in primary health centers and university 
hospitals in the city of Helsinki, were used as controls. This group comprised of 
207103 individuals.
Validity of the BMD reference values, was tested in 199 healthy Finnish chil-
dren ranging in age from 7 to 19 years.
4.1.1 Inclusion criteria for patients 
Study I: Consecutive patients between the ages of 4 and 18 years who fulfilled 
the revised criteria of JIA according to the International League of Associations 
for Rheumatology (ILAR) classification. The time since diagnosis of JIA had to 
be at least 2 years, and the patient should have been on systemic GC treatment 
for at least 3 months and treated at the Hospital for Children and Adolescents, 
University of Helsinki, since diagnosis.
Study II: Children, adolescents, and young adults who had undergone RTx, LTx, 
or HTx under the age of 18 years during 1983-2002 and who were treated at 
the Hospital for Children and Adolescents, University of Helsinki. Young adults 
who had already been transferred to adult units for follow-up were also in-
vited to participate.
Studies III and IV: Consecutive children and adolescents who had undergone 
LTx before the age of 16 years (III) or RTx before the age of 18 years (IV) at least 
6 months before the date of enrollment and who were aged between 4 and 20 
years at the time of the study. All transplantations had been performed at the 
Hospital for Children and Adolescents, University of Helsinki, and follow-up 




4.1.2 Treatment of patients with juvenile idiopathic arthritis
The pharmacological treatment of JIA was individualized and based on the 
subtype of JIA and the severity of the disease. Treatment of patients with 
mild disease, such as oligoarthritis without uveitis, was usually initiated using 
intra-articular GCs or nonsteroidal anti-inflammatory drugs or a combination 
of these. The most commonly used nonsteroidal anti-inflammatory in our pa-
tients was naproxen at a daily dose of 15-20 mg/kg. If the symptoms of oligoar-
thritis persisted or worsened, or if the patient already had a polyarticular or 
systemic disease, a more aggressive therapy was initiated. Oral GC, in our pa-
tients usually prednisolone, was usually started with a dose of 1-2 mg/kg/daily 
for some weeks, and the dose was tapered as soon as possible. An alternate-
day GC regimen was preferred. Patients with a systemic disease were on high 
GC doses longer and also intravenous GC therapy was used in these patients. 
Disease-modifying anti-rheumatic drugs, such as MTX, sulfasalazine, Aza, and 
CsA were used as second-line drugs, with MTX most often being administered 
at a weekly dose from 10 to 20 mg/m2. Twenty (33%) of our patients did not 
respond adequately to conventional drug treatment, and TNF-α antagonists 
were used for them. 
4.1.3 Immunosuppressive medication after transplantation
The transplant patients were treated primarily with triple-drug immunosup-
pressive medication, including CsA, Aza, and methylprednisolone (MP). Since 
year 1999, the liver and renal transplant patients also received basiliximab as 
an induction. Antithymocyte globulin was used as an induction therapy in HTx. 
CsA was started perioperatively and the target trough levels were 300-400 
μg/L after LTx or HTx, and 250-300 μg/L after RTx during the first weeks. The 
doses were then slowly reduced to attain levels of 70-100 μg/L at one year and 
thereafter. MP was given 1-3 mg/kg/day during the first postoperative days and 
tapered to 0.25 mg/kg/day at 2 weeks. A low-dose alternate-day MP regimen 
was commenced at 3-6 months in RTx patients (mean daily dose 0.12 mg/kg) 
and at 6 months in LTx or HTx recipients (mean daily dose 0.19 mg/kg). After 
the first postoperative year, the MP dose was not increased with growth. Aza 
was given 2 mg/kg/day for the first 2 weeks and then reduced to 1 mg/kg/day, 
and increased to 1.3-1.4 mg/kg/day at 3 or 6 months, when MP was changed to 
alternate-day dosing. Acute rejections were primarily treated with MP (3 mg/
kg/day) for 5 days. If features of chronic rejection or recurrent acute rejections 
were observed in the renal, liver, or heart biopsies, the patients were switched 




4.2.1 Study design and data collection
All studies consisted of a retrospective part in which hospital charts were re-
viewed for the underlying disease and treatment characteristics, growth, pu-
bertal development, and previous fracture history. The mean weight-adjusted 
(mg/kg) daily doses of MP, CsA, and Aza were calculated during the annual 
follow-up visits (II). Orally administered GCs were converted to prednisolone 
equivalents in JIA patients and all doses used after the diagnosis were record-
ed (I). Absolute and weight-adjusted cumulative doses of MP, including the 
doses used for rejection treatment, were calculated for each transplant pa-
tient. For LTx patients, the whole postoperative period was included and for 
RTx recipients a 3-year period preceding the study (III, IV). The patients and/
or their parents filled out questionnaires on the patient’s fracture history, and 
the fractures were also specially asked about during the study period. For each 
reported fracture, the localization and mechanism of injury were recorded. 
Radiographic documentation was obtained from hospital records for all frac-
tures. A high-energy trauma was defined as a fall of >3 m or a traffic accident 
(I-IV).
In the cross-sectional part of the study, laboratory and anthropometric data, 
BMD evaluation with IVA images, spinal radiographs, evaluation of pubertal 
development, and data collection by questionnaires were performed concur-
rently (I, III, IV). All patients were clinically assessed by two pediatric rheuma-
tologists (I) or by a pediatric nephrologist (III, IV). Global assessment of overall 
well-being by the parents or guardians, physician’s global assessment of dis-
ease activity, and Childhood Health Assessment Questionnaire (CHAQ) were 
administered to all patients with JIA. A 3-day dietary recall was obtained for 
patients with arthritis, and based on these recordings, the average daily in-
takes of calcium and vitamin D were calculated for each patient using the com-
puter program AIVO 2000-Diet32, version 1.4.2.1, which is based on the Finnish 
dietary references for 1998 (I). A detailed clinical examination of the spine and 
extremities was performed on all transplant patients in Study II by two ortho-
pedic surgeons. Information on the use of dairy products and calcium or vita-
min D supplements were obtained by a detailed review in Studies I, III, and IV. 
Fracture incidence was assessed also prospectively during a 5-year prospective 
study period in Study II. Fracture history was systemically recorded at yearly 
follow-up visits during this study, and a thorough clinical examination of the 
spine was performed at the beginning and at the end of this prospective part 
of the study. The development of BMD was also prospectively evaluated during 
a 2-year period in 14 children with a history of a recent RTx (IV).
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4.2.2 Growth assessment 
Height was measured with a Harpenden stadiometer and weight in thin under-
wear with an electric scale; values were compared with Finnish growth charts 
(Sorva et al. 1990, Pere 2000). Height SD score (height Z-score) was defined as 
deviation of height, in SD units, from mean height for age and sex. Weight 
was expressed as a height-adjusted value, as a percentage of the mean ratio 
in a normal population of the same gender and height, according to Finnish 
standards (Sorva et al. 1990, Pere 2000). Body mass index (BMI) was calculated 
as weight in kilograms divided by square of height in meters (kg/m2) . Pubertal 
maturation was assessed according to Tanner (1962) as part of the clinical as-
sessment (I, III, IV).
4.2.3 Biochemistry
The following laboratory parameters were assessed in Studies I, III, and IV. 
Plasma calcium, phosphate, alkaline phosphatase, and creatinine were meas-
ured using standard methods. Plasma concentrations of alanine aminotrans-
ferase, gamma glutamyltransferase, and total and conjugated bilirubin were 
analyzed using standard methods (III), and blood urea nitrogen and magne-
sium were measured (IV). Reference ranges for plasma alkaline phosphatase 
were age- and sex-dependent, and the measured values were transformed into 
Z-scores using normal values to allow for cross-sectional comparison. Serum 
25-OH-D was assessed by liquid chromatography (Turpeinen et al. 2003), 
1,25-(OH)2D by RIA (only in Study IV), and plasma fasting PTH by an immuno-
luminometric method. Girls >8 years and boys >10 years were assessed also for 
serum follicle-stimulating hormone, luteinizing hormone, and estradiol or tes-
tosterone. All blood samples were drawn between 7:30 and 10:00. Urine was 
analyzed for calcium/creatinine ratio in all patients (I, III, IV). 
Glomerular filtration rate (GFR) was measured by  51Cr-EDTA clearance, and the 
measured clearances were corrected for a standard body area of 1.73 m2 (III, 
IV).
4.2.4 Imaging studies
4.2.4.1 Bone mineral density measurement
Data on LS BMD measurements, carried out as part of the routine posttrans-
plantation follow-up, were collected from hospital records for each patient 
(III, IV). In the cross-sectional studies, BMC and aBMD of the LS (L1-L4), femoral 
neck, total hip, and whole body were measured with DXA (Hologic Discovery 
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A, pediatric software, version 12.4). All measured values were transformed into 
Z-scores using the equipment-specific age- and sex-adjusted reference data-
base for the United States Caucasian children. The validity of these reference 
values was tested in a cohort of 199 healthy Finnish children (125 girls and 74 
boys; age range 7.4-18.8 years, median 13.1 years) who were assessed with the 
same DXA equipment as part of an ongoing study evaluating bone health in 
healthy schoolchildren in the Helsinki area. Their median BMD Z-scores were 
0.0, +0.1, and 0.0 for the LS, total hip, and whole body, respectively, confirming 
that the use of equipment-specific reference data in this study was justified (I, 
III, IV). Whole-body lean tissue mass (LTM) and BMC were obtained by DXA. 
The BMC/LTM ratio was calculated for both height and age according to Högler 
et al. (2003), and the results were transformed into Z-scores. The BMC/LTM ra-
tio was used to correct the BMC values for body size and muscle mass (I, III).
The aBMD Z-scores were calculated for both calendar age and bone age. The 
correction for skeletal maturation instead of “height age” was used because 
bone age was delayed by ≥ 1 year in 24% of JIA patients, 43% of liver trans-
plant patients, and 42% of renal transplant patients. The aBMD Z-scores cor-
rected for bone age were higher than the values calculated for calendar age 
at all measured sites. Therefore, bone-age-adjusted Z-scores were used in the 
analysis of the study measurements; only calendar-age-adjusted Z-scores were 
available for the longitudinal analysis. 
4.2.4.2 Radiographic evaluation
Bone age was determined from a plain radiograph of the left hand according 
to Greulich and Pyle (1959). To detect vertebral compression fractures, antero-
posterior and lateral images of the thoracic and LS (IVA) were obtained once 
for each patient using the DXA scanner (I-IV). If the LS aBMD Z-score was 
≤-2.0, if a VFx was suspected in IVA images, or if the vertebrae could not be 
sufficiently visualized in IVA images, standard spinal radiographs were taken (I, 
III, IV). Vertebral deformities and compression fractures were assessed accord-
ing to the classification of Mäkitie et al.(2005). This method was developed for 
the evaluation of vertebral body morphology changes in chronically ill children 
with secondary osteoporosis. The vertebral changes were classified as normal 
(grade 0 or 1), anterior wedge deformities (only the anterior part of the verte-
bra compressed), or compression deformities (also the middle and/or posterior 
part of the vertebra are compressed). These abnormal changes were further 
classified as mild (2a; 20-49% anterior height reduction) or severe (2b; ≥50% 
anterior height reduction) anterior wedge deformities, or mild (3a; 20-49% 
mild height reduction) or severe (3b; ≥50% middle height reduction) compres-
sion deformities (I-IV). 
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Posteroanterior and lateral radiographs of the thoracic and LS were obtained 
at the final follow-up of the prospective part of the study for subjects with a 
history of VFx, back pain, increased kyphosis, rib hump, or other spinal deform-
ity in the clinical examination. For the remaining patients, these images were 
obtained by the DXA scanner (II).
4.3 Ethical considerations
The study protocols were approved by the Ethics Committee of the Hospital for 
Children and Adolescents, University of Helsinki. A written informed consent 
was obtained from all patients and/or their guardians.
4.4 Statistics
Descriptive data were reported as medians and ranges or as means ± SD. Simple 
regression analysis was used for correlations, unpaired two-tailed Student’s 
T-test to compare means, and the Mann-Whitney U-test to compare nonnor-
mally distributed variables. Comparisons between three or more groups were 
made by ANOVA, and for nonparametric data the Kruskall-Wallis test was used. 
The Chi-square test was applied when nominal data were compared (I, III, IV).
The Kaplan-Meier test was used to estimate the probability of patients remain-
ing free of fractures during the follow-up, and the stratified Kaplan-Meier 
curves were applied to assess the risk factors for fractures after transplanta-
tion (II). Age-and sex-adjusted hazard ratios and 95% confidence intervals for 
different fracture types in the patients and controls were calculated by Cox’s 
proportional hazard regression model, and a multicovariate Cox’s proportional 
hazard regression model was used to assess the effects of different risk factors 
for developing any type of fracture in the patient group (II).
Multivariate logistic regression was used to identify and determine odds ratios 
(ORs) and 95% confidence intervals for significant predictors of low BMD (IV). 




Bone health was evaluated in 62 (19 males) children and adolescents with JIA 
who had been treated with GCs and multiple drug combinations and were 
aged between 4 and 18 years (I). In the epidemiological study, the incidence 
of fractures was evaluated in a population-based cohort of 196 (121 males) 
children, adolescents, and young adults with a history of solid organ transplan-
tation before the age of 18 years (II). Bone health evaluation was performed 
on 40 (21 males) LTx and 106 (65 males) RTx patients aged between 4 and 20 
years and who had at least a 6-month follow-up after LTx or RTx. All of these 
patients were receiving calcineurin inhibitor, antimetabolite, and low- dose 
MP (III, IV).
The clinical characteristics of the patients are shown in Table 4. Most of the 
subjects with JIA were of normal stature, while about one-fourth of the chil-
dren and adolescents after transplantation had a height Z-score below -2.0. 
Overweight was found in 38% after RTx. The median heights and height-ad-
justed weights of the LTx and RTx patients in the cross-sectional part of the 
study are presented in Table 4 and during the longitudinal follow-up in Figure 
7. Bone age was delayed by ≥ 1 year in 24% of JIA, 43% of liver, and 42% of 
renal transplant patients. Since bone age was significantly delayed in such a 
large proportion of subjects, BMD values were corrected for bone age. The 
bone age-adjusted BMD values were higher in all of our study groups, and 
these corrected values, presented in Figure 8, were used in the cross-sectional 
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Figure 7. Medians for height, height-adjusted weight, and lumbar spine bone 
mineral density (BMD) for chronological age during posttransplantation follow-
up in 106 children and adolescents with a renal graft (A) and in 40 children and 
adolescents with a liver transplant (B). Height and BMD are expressed in SD units 
(Z-score) and weight in percentages. 
Figure 8. Bone age-adjusted lumbar spine and whole-body BMD Z-scores in con-
trols and patients with juvenile idiopathic arthritis (JIA), liver transplantation (LTx), 





Median serum vitamin D and PTH of subjects are shown in Table 5 and Figure 
9. A vitamin D level below 37 nmol/L was measured in 26% of patients with 
JIA, and in 13% and 14% of  patients with a liver or renal graft, respectively 
(Table 5). When the vitamin D samples obtained in winter (from October to 
March) and in summer (from April to September) were analyzed separately, 
no seasonal variation was observed in any of the patient groups. The lowest 
PTH values were found in patients with JIA and the highest in the RTx group. 
None of the patients with JIA or a history of LTx had PTH values above 100 ng/L, 
while in the RTx patients PTH was above 100 ng/L in 25% of patients (Table 
5). A vitamin D value ≥ 80 nmol/L was measured in 3% of JIA patients, 28% of 
LTx patients, and 25% of RTx patients. Serum calcitriol was within the normal 
range (48-110 pmol/L) in most of the patients; nine (8%) of the RTx patients 
had subnormal values (IV).
Most (83%) of the LTx patients were on vitamin D substitution, and 71% of the 
RTx patients had either vitamin D or alfacalcidol substitution, but only 32% of 
the JIA patients were on vitamin D substitution (Table 5). 
Table 5. PTH and vitamin D values in patients with a history of juvenile idiopathic arthritis (JIA), 
liver transplantation (LTx), or renal transplantation (RTx).   
  Study I Study III Study IV 
 JIA LTx RTx 
  n = 62 n = 40 n = 106 
Vitamin 25-OH-D nmol/L, median (range) 49 (13-87) 61 (17-121) 60 (15-166) 
Vitamin 25-OH-D < 37 nmol/L, n (%) 16 (26) 5 (13) 15 (14) 
Vitamin 25-OH-D  80 nmol/L, n (%) 2 (3) 11 (28) 26 (25) 
PTH ng/L, median (range) 32 (12-38) 43 (16-96) 69 (13-558) 
PTH > 100 ng/L, n(%) 0 0 26 (25) 
Patients on vitamin D substitution, n (%) 20 (32) 33 (83) 53 (50) 




Figure 9.  Serum vitamin D and PTH concentrations in patients with juvenile idi-
opathic arthritis (JIA), liver transplantation (LTx), or renal transplantation (RTx).
5.2 Fractures
5.2.1 Nonvertebral fractures
Four (6%) of the JIA patients had sustained a nonvertebral fracture after the 
onset of JIA (I). The proportion of Tx patients with nonvertebral fractures was 
highest in subjects in the epidemiological study (II) and lowest in the RTx pa-
tients, 19% and 9%, respectively (II, IV). Five (13%) of the LTx patients had a 
nonvertebral fracture history (Table 6). The annual incidence of nonvertebral 
fractures was 3.8% after solid organ transplantation performed during child-
hood or adolescence and threefold higher in the study group than in the con-
trol population (II). No correlation was found between aBMD values or weight-
adjusted cumulative GC doses and peripheral fractures in patients with JIA or 
renal transplantation (I, IV). In LTx patients, the MP exposure was lower in 




The number and localization of VFx are presented in Table 7 and Figure 10. In 
Study II, half of the patients with VFx had symptoms, e.g. back pain, and 11% 
needed operative fracture treatment. In the other studies (I, III, IV), most of the 
patients reported no pain, and none required operative treatment. Most of the 
fractures were detected in the thoracic spine (Figure 10).
 
Table 6. Nonvertebral fractures and their localization in study subjects.   
  Study I Study II Study III Study IV 
 JIA Epidemiological LTx RTx 
Number of patients 62 196 40 106 
Number and proportion (%) of patients with fracture  4 (6) 38 (19) 5 (13) 10 (9) 
Total number of fractures 4 64 10 12 
Localization of fractures     
Upper extremity  37 9 7 
Humeral  2 1  
Antebrachium 1 20 4 6 
Other 2 15 4 1 
Lower extremity  27 1 5 
Femoral/pelvic  3 1  
Tibial/ankle  11  1 
Other 1 13   4 
 
Table 7. Vertebral fractures in study subjects     
  Study I Study II Study III Study IV 
  JIA Epidemiological LTx Rtx 
Number of patients 62 196 40 106 
Number and per cent of patients with VFx (%) 6 (10) 37 (19) 7 (18) 8 (8) 
Total number of fractured vertebrae 14 102 19 17 
Symptomatic patients, n (%) 0 (0) 18 (50) 0 (0) 2 (25) 
VFx = vertebral fracture         
RESULTS
47
Figure 10. Number and localization of vertebral fractures in 62 patients with JIA 
(A), 40 patients with liver transplantation (B), and 106 with renal transplantation 
(C).
In patients with arthritis, the duration of GC treatment or weight-adjusted cu-
mulative GC dose did not differ in those with VFx compared with other study 
subjects, and none of the patients with VFx had bone age-adjusted aBMD 
Z-scores below -2.0. No gender difference was found in the prevalence of VFx. 
In the epidemiological study of fracture incidence, older age at the time of 
transplantation, higher BMI, male gender, LTx, and a history of nonvertebral 
fracture prior to transplantation increased the risk for VFx, while the type of 
graft, retransplantation, or number of acute rejections were not associated 
with the risk of VFx. The age, and sex-adjusted hazard ratio with 95% confi-
dence interval for VFx was 61.3 (CI 40.7-92.4). The average weight-adjusted 
(mg/kg) maintenance doses of CsA, Aza, or MP did not correlate with vertebral 
fractures (II).
The LTx subjects (III) with fractures were significantly older at the time of Tx 
(p = 0.002), more recently transplanted (p = 0.019), had higher BMI (p = 0.029) 
and whole-body fat percentage (p = 0.025), and lower aBMD Z-scores at the 
LS (p = <0.001), femoral head (p = 0.048), and whole body (p = 0.030) than 
those without VFx (Table 8). No difference was found in MP exposure. Five of 
the seven patients with VFx had LS BMD Z-score ≤ -2.0. No differences were 
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observed in the laboratory parameters. All patients with VFx were adolescents 
(age range 12.0-17.3 years), and five of the seven had undergone transplanta-
tion after the age of 10 years.
The BMD Z-scores in RTx patients with VFx did not differ from the values of 
nonfractured patients (IV). The patients with VFx were older at the time of 
the study and had longer time since renal transplantation, but their age at 
transplantation did not differ from the others (Table 8). Nor did laboratory 
parameters, measured GFR, or weight-adjusted MP dose during the preceding 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3 Bone mineral density 
5.3.1 Retrospective analysis of bone mineral density development
Altogether 208 and 478 lumbar spine BMD assessments were available for the 
longitudinal analysis of BMD in 40 LTx patients and 106 RTx patients, respec-
tively (III, IV). The median LS BMD Z-score was -2.2 at the time of transplan-
tation and ≤ -2.0 in 75% of the LTx patients (III). It then gradually increased 
during the following years to a peak value of -0.5 at seven years (Figure 7 
B) posttransplantation when the Z-score was ≤ -2.0 in 22% of the subjects. 
Complete BMD data for the pubertal years were available for 10 LTx patients. 
In eight of these the aBMD Z-score decreased by ≥ 0.7 during puberty and was 
significantly subnormal (mean LS Z-score -1.9, range -0.8- -4.4) at completion of 
puberty in all of them (Figure 11 A, B).
             A.
             B.
Figure 11. Development of lumbar spine BMD Z-score over puberty in four females 
(A) and six males (B) after LTx.
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In RTx patients, the median LS BMD Z-score was -0.4 at the time of RTx and 
≤ -2.0 in 9% of the subjects. It decreased postoperatively (median Z-score -1.0 
at year one), but increased during the following years to attain a peak value 
of -0.2 at five years postoperatively (Figure 7 A). During puberty the median 
aBMD Z-scores increased in male subjects, in contrast to females, for whom 
the scores decreased (Figure 12). Concurrently, the median height Z-score re-
mained at -1.0 nine years after RTx despite catch-up growth (Figure 7 A).
Figure 12. Development of lumbar spine BMD Z-score over puberty  in girls and 
boys with RTx.The curves represent median values.
5.3.2 Cross-sectional analysis
A comprehensive aBMD analysis with DXA and clinical examination were per-
formed on JIA, LTx, and RTx patients. The median aBMD values for the LS and 
whole body were higher when corrected for bone age. The median LS BMD 
Z-scores were -0.4, -1.2, and -0.5, and the median whole-body BMD Z-scores 
were -0.1, -0.8, and -0.3 in the patients with JIA, LTx, and RTx, respectively. The 
LS BMD Z-scores were ≤ -2.0 in three of the JIA patients, five of the LTx patients, 
and four of the RTx patients and for the whole body in one, six, and four pa-
tients, respectively (I, III, IV) (Table 9).
Table 9. Bone mineral density in children with juvenile idiopathic arthritis, liver, or renal transplantation 
  Study I Study I Study IV 
 JIA  LTx  RTx  
  n = 62 n = 40 n = 106 
Lumbar spine aBMD Z-score  -0.4 (-2.8 - +1.8)  -1.2 (-3.8 - +0.8)  -0.5 (-2.8- +2.4) 
Lumbar spine Z-score  -2.0, n (%) 3 (5) 6 (15) 4 (4) 
Hip aBMD Z-score  -0.1 (-2.1 - +2.4)  -0.9 (-2.6- +0.9)  -0.2 (-3.0- +2.9) 
Hip aBMD Z-score  -2.0, n (%) 1 (2) 5 (13) 6 (6) 
Whole-body aBMD Z-score  -0.1 (-1.9 - +2.4)  -0.8 (-3.6 - +0.6)  -0.3 (-3.2- +1.8) 





A prospective more thorough evaluation of BMD development during the first 
2 years after RTx was performed in 14 patients. It showed a decrease in BMD 
at 6 months after RTx in all 8 male subjects and in 4 of the 6 female subjects. 
Thereafter the BMD values recovered.
5.4 Determinants of bone mineral density
We studied various parameters in relation to BMD to identify the clinical and 
treatment-related factors that may predispose to impaired BMD in patients 
with JIA or a solid organ transplant.
5.4.1 Age and duration of dialysis treatment
No correlation was found between the age at onset of JIA and aBMD Z-scores 
(I). Children who had undergone LTx before the age of two years had statisti-
cally higher aBMD Z-scores at all measured sites than those who were trans-
planted at an older age. However, the BMD values of children with RTx below 
two years of age did not differ from the other subjects (Table 10). Similarly, 
if the LTx was performed below the age of 10 years, the patients had higher 
BMD Z-scores for LS, hip, and whole body, with p-values of 0.005, 0.007, and 
0.006, respectively. The six patients with LS Z-score ≤ -2.0 were transplanted at 
an older age (14.1 vs. 2.0 years, p = 0.002) (III). Seventeen patients (16%) on 
dialysis for more than two years before RTx had lower LS aBMD Z-scores (IV). 
 
Table 10. Clinical characteristics and bone mineral density parameters in children and adolescents after liver or renal 
transplantation at the age of  2 years.        
    Age at LTx     Age at RTx   
   2 years > 2 years p-value   2 years > 2 years p-value 
    n = 19 n = 21     n = 36 n = 70   
Age at study time, years  10.9 ± 4.0 14.2 ± 4.5 0.011  9.8 ± 4.1 12.7 ± 4.2 ns 
Follow-up after transplantation, years  9.6 ± 4.0 6.0 ± 5.3 0.024  8.4 ± 4.0 5.4 ± 4.7 0.002 
Height Z-score   -1.2 ± 1.2  -1.3 ± 1.4 ns   -1.2 ± 1.0  -1.4 ± 0.9 ns 
Height-adjusted weight, %  +6.6 ± 14.3  +9.2 ± 20.4 ns   +8.4 ± 13.6  +17.8 ± 26.9 ns 
aBMD Z-score for lumbar spine    -0.7 ± 0.6  -1.7 ± 0.9 0.002   -0.5 ± 0.9  -0.4 ± 1.0 ns 
aBMD Z-score for hip    -0.5 ± 0.8  -1.3 ± 0.9 0.004   -0.3 ± 1.0  -0.2 ± 1.2 ns 
aBMD Z-score for whole body     -0.5 ± 0.8  -1.3 ± 1.1 0.030    -0.1 ± 1.0   -0.4 ± 1.0 ns 




5.4.2 Renal function 
All of the patients with JIA had normal plasma creatinine, and it showed no 
correlation with aBMD values (I). The measured GFR was above 90 mL/min/1.73 
m2 in 13 (33%), between 60 and 90 mL/min/1.73 m2 in 18 (45%), and between 
30 and 59 mL/min/1.73 m2 in 9 LTx patients (22%) (III). In RTx patients, GFR was 
above 90 mL/min in 10 (9%), between 60 and 90 mL/min in 35 (33%), between 
30 and 59 mL/min in 52 (49%), and below 30 mL/min in 9 subjects (9%). None of 
the patients were on dialysis (IV). No statistical difference was found between 
these groups in aBMD values at any measured site (III, IV).
5.4.3 Vitamin D and parathyroid hormone
Twenty-six (25%) of the RTx patients had a 25-OH-D value ≥ 80 nmol/L. Their 
aBMD Z-scores for the hip were higher than in the other RTx subjects (+0.3 vs. 
–0.4, p = 0.0023). Fifteen subjects (14%) had a vitamin D value below 37 nmol/L, 
and they had lower aBMD Z-scores for the hip and whole body, -0.9 vs. -0.2, 
p = 0.019, and -1.0 vs. -0.1, p = 0.002, respectively (IV). In a simple regression 
analysis, no correlation was found between PTH or vitamin D values and aBMD 
Z-scores in JIA or liver transplant patients (I, III). In Study I, the JIA patients with 
vitamin D values below 37 nmol/L had statistically higher PTH values (45 vs. 33, 
p = 0.007). No correlation was present between serum 1,25 (OH)2D and aBMD 
values (IV).
5.4.4 Medication
The total duration of GC treatment or weight-adjusted cumulative GC dose in 
patients with JIA showed no correlation with aBMD values in any measured 
site. JIA patients treated with TNF-α antagonists had significantly higher mean 
duration (1993 days vs. 734 days, p = < 0.001) and mean cumulative weight-
adjusted dose (387 mg/kg vs. 99 mg/kg, p = < 0.001) of GC than patients not 
taking TNF-α antagonists, but their aBMD values did not differ from the values 
of other JIA patients. The aBMD values of patients who had been on GC treat-
ment during the year preceding the study did not differ from the others (I). 
The cumulative MP exposure (mg/kg/day) during the total posttransplantation 
period after LTx did not correlate with aBMD values in any measured site (III). 
Also when the 36 patients with less than three years since RTx were excluded, 
no correlation was found between cumulative weight-adjusted MP dose and 
aBMD values in the remaining 70 subjects (IV).
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5.4.5 Predictors for low bone mineral density in logistic regression 
analyses
Logistic regression analysis was performed to evaluate possible predictors for 
aBMD Z-scores ≤ -1.0 at the LS or hip in RTx patients (IV, Table 11).
Gender alone was not a significant predictor, but when combined with pa-
tient’s age at study assessment it was highly significant. The OR for the LS and 
hip aBMD ≤-1.0 in girls over 15 years were 56.26 (95% CI from 5.17 to 611.82) 
and 13.47 (95% CI from 1.17 to 154.69), respectively. When comparing the 9 
girls and 22 boys aged >15 years with each other, no difference was observed 
in the duration of dialysis, age at RTx, time since RTx, height Z-score, height-ad-
justed weight, or GFR. A PTH value over 100 ng/L at the time of the study was 
a significant independent predictor for a low LS aBMD Z-score, with OR 4.03 
(95% CI from 1.37 to 11.85), and similarly, vitamin D value below 40 nmol/L at 
the study time for a low hip aBMD, with OR 11.62 (95% CI from 3.31 to 40.86). 
Cumulative weight-adjusted MP dose over 150 mg/kg during the preceding 
three years was an independent risk factor for aBMD Z-score ≤ -1.0 in the LS, 
with OR 5.72 (95% CI from 1.52 to 21.56). 
In the logistic regression analysis, duration of dialysis treatment, age at trans-
plantation, time since transplantation, GFR, and vertebral or nonvertebral frac-
tures were not significant predictors for BMD. 
 
Table 11. Odds ratios and 95% confidence intervals for factors predicting lumbar spine and hip 
BMD Z-score  -1.0 in pediatric renal transplant patients.  
      
Risk factor BMD Z-score for  BMD Z-score for  
 lumbar spine  -1.0 hip  -1.0 
  n = 31 n = 22 
   
Age at time of study > 15 years + female gender 56.26 (5.17 - 611.82) 13.47 (1.17 - 154.69) 
n = 9 p = 0.0007 p = 0.033 
   
fP-PTH > 100 ng/L 4.03 (1.37 - 11.85) 1.94 (0.51- 7.35) 
n = 26 p = 0.009 p = 0.317 
   
S-D-25 < 40 nmol/L 2.31 (0.60 - 8.95) 11.62 (3.31 - 40.86) 
n = 18 p = 0.215 p = 0.0001 
   
Cumulative weight-adjusted MP dose during 5.72 (1.52 - 21.56) 1.87 (0.31 - 11.12) 
previous 3 years > 150 mg/kg p = 0.008 p = 0.484 
n = 15     
Logistic regression model was used for analysis   







JIA and solid organ transplantation have been associated with changes in bone 
metabolism. Several factors may lead to impaired bone health in children with 
JIA or a history of Tx. Chronic inflammation, GCs, and limited physical activity in 
patients with JIA, and pre-existing bone disease, GCs, calcineurin inhibitors, im-
paired renal function, and changes in vitamin D metabolism in Tx patients are 
thought to have an impact on bone health. We investigated the incidence and 
prevalence of fractures, distribution of BMD, and vitamin D status in pediatric 
patients with GC exposure and attempted to identify clinical and treatment-
related factors that may negatively affect bone health in these subjects.
6.1 Bone health characteristics in patients with juvenile 
idiopathic arthritis
Previous studies have reported a high prevalence of osteoporosis in children 
and adolescents with JIA. The last decade has brought new treatment mo-
dalities to children with JIA, but how these medications impact overall skeletal 
health is unknown. In this study, we evaluated bone health in 62 children with 
JIA.
The clinical course of JIA is variable; in some patients, the disease remains ac-
tive for a long time and these individuals may enter adulthood with active 
disease (Ravelli 2004). Several cross-sectional long-term follow-up studies have 
reported reduced BMD in adults with a history of JIA (Zak et al. 1999, French 
et al. 2002). Zak et al. (1999) evaluated 65 adult patients (mean age 32 years) 
with a history of JIA and found osteopenic (T-score < -1.0) LS and hip aBMD 
values in 43% and 53% of the subjects, respectively. In the study by French et 
al. (2002), 28% of adult patients with JIA were osteopenic. Low aBMD values 
in early adulthood may predispose to increased risk and early presentation of 
fragility fractures. 
Several factors may negatively affect bone health in patients with JIA. Chronic 
inflammation may result in generalized or periarticular bone loss (Haugeberg 
et al. 2003, Strand and Kavanaugh 2004). Cytokines and growth factors pro-
duced by synovial tissue may increase osteoclast formation, activity, and/or sur-
vival, and thus increase bone resorption (Gravallese 2002). Limited physical ac-
tivity and reduced muscle forces acting on bone may pose an additional risk for 
osteoporosis (Häkkinen et al. 2004, Lindehammar and Lindvall 2004, Burnham 
et al. 2006b). However, medications, especially GCs, have been regarded as the 
main threat to skeletal health in patients with JIA. Both systemically and intra-
articularly administered GCs can reduce bone formation and increase its resorp-
tion (Canalis 2003). MTX has been reported to cause osteopenia when used to 
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treat childhood malignancies (Mandel et al. 2004). The dosing in JIA is substan-
tially lower and does not seem to have adverse effects on bone (Cranney et al. 
2001, Cimaz 2002). Furthermore, both calcium and vitamin D intake may be 
suboptimal, and delayed puberty, which is common in patients with JIA, may 
negatively affect bone mass accrual (Rusconi et al. 2003, Hillman et al. 2008). 
In our patients with JIA, the median bone-age-adjusted aBMD Z-scores were 
-0.4, -0.1, and -0.1 for the LS, hip, and whole body, respectively. Three (5%) 
of the patients had aBMD Z-score ≤ -2.0 for the LS, one (1%) for the hip, and 
one (2%) for the whole body. The observed aBMD values were higher than 
reported in previous studies, but below the values of healthy schoolchildren 
in Finland, especially in the lumbar region. Most of our patients had normal 
stature. While all of the patients were on anti-rheumatic drug treatment (MTX, 
GC, TNF-α-antagonist, hydroxychloroquine, or sulfasalazine), a large propor-
tion (55%) were in clinical remission. The majority (90%) of the subjects were 
able to participate in normal physical education at school. The positive effect 
of physical training on bone health is widely recognized and may partly explain 
the satisfactory aBMD values. 
The proportion of patients with a history of nonvertebral fracture did not dif-
fer from that of the normal pediatric population. Six (10%) of our patients had, 
however, asymptomatic VFx. This number is high, particularly in view of the 
satisfactory aBMD values. This emphasizes the importance of active screening 
for VFx. DXA alone is not sufficient in detecting VFx, as none of our patients 
with VFx had an aBMD Z-score ≤ -2.0. Therefore, spinal imaging is also needed 
for adequate fracture evaluation.
Neither the total duration nor the cumulative weight-adjusted dose of GC 
correlated with aBMD values or fractures. These results are in line with some 
previous reports that show low aBMD values even in JIA patients without GC 
exposure (Lien et al. 2003). In our subjects, no difference in bone health was 
observed between those patients receiving GC treatment during the survey 
and those who had previously been exposed to GC.
TNF-α is known to be an important mediator in various inflammatory condi-
tions and in postmenopausal osteoporosis. TNF-α directly inhibits osteoblast 
differentation, function, and survival and promotes osteoclastogenesis (Feng 
2005). TNF-α antagonists have provided a new effective treatment modality 
also in pediatric patients with arthritis. In addition, they may prevent bone 
loss directly by regulating osteoclast formation and activation or by decreasing 
the amount of circulating cytokines (Saidenberg-Kermanac’h et al. 2004, Feng 
2005), and indirectly by allowing reduced GC dosing and improved physical ac-
tivity (Lahdenne et al. 2003, Strand and Kavanaugh 2004, Simonini et al. 2005). 
During anti-TNF therapy soluble bone turnover markers decrease significantly 
and aBMD values significantly increase in adult patients with rheumatoid ar-
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thritis (Lange et al. 2005, Seriolo et al. 2006, Torikai et al. 2006). Twenty (32%) 
of our patients had been on TNF-α antagonists. This may partly explain the 
better aBMD values in our subjects. However, the small number of patients 
and the lack of prospective data in our study do not allow any firm conclusions 
to be made. Further longitudinal studies in pediatric patients are needed to 
elucidate the potential skeletal benefits of anti-TNF therapy.
6.2 Bone health after solid organ transplantation
Transplantation has become an established treatment modality for several dis-
eases, including acute and chronic liver failure, end-stage renal disease, and 
heart failure. The number of people living with a graft has increased stead-
ily during the last two decades. While the overall survival has improved, new 
problems, such as osteoporosis and fragility fractures, have emerged. The 
present epidemiological study showed a high incidence of fractures in 196 sub-
jects who had undergone Tx during childhood or adolescence. 
Because the overall incidence of fractures in the adult studies was high and no 
previous prospective studies were published on fracture incidence in pediatric 
Tx patients, we performed a retrospective and longitudinal study to define the 
fracture incidence in Finnish solid organ transplant recipients. Our study com-
prised 196 children, adolescents, and young adults with a kidney, liver, or heart 
transplant at or before 18 years of age. Over one third of these patients had 
sustained one or more fractures postoperatively, and 61% of the 166 fractures 
were vertebral. The annual incidence for vertebral and nonvertebral fractures 
postoperatively was 5.7%, and 3.8%, respectively. The incidence was 160-fold 
higher for the VFx and threefold higher for the non-vertebral fractures as com-
pared with the control population. The number of vertebral and non-vertebral 
fractures in this epidemiological study was higher than in our subsequent stud-
ies on younger patient cohorts with a history of LTx or RTx. This may be due to 
a longer follow-up time and a larger proportion of patients who had already 
passed their adolescent growth spurt, period of the highest fracture incidence 
also in healthy children (Bailey et al. 1999).
In our patient group, one-half of the VFx were asymptomatic. This signifies that 
if VFx are not specifically searched for, many of them will elude proper diagnosis 
and treatment. Eight (11%) of the patients with VFx had needed operative treat-
ment. This is a high proportion compared with the observations in our subsequent 
studies on pediatric LTx and RTx patients; none of them were operated. Higher GC 
doses were used in the oldest patients. The control of secondary hyperparathy-
roidism in patients on dialysis has also changed within the last decade. These fac-
tors may partly explain the different fracture patterns in the studies. However, this 
study showed that pediatric patients are also prone to fractures, and we therefore 
assessed bone health separately in children and adolescents after LTx or RTx.
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6.3 Bone health in children and adolescents after liver 
transplantation
Surgical techniques, intensive care treatment, and immunosuppressive medica-
tion have improved greatly during the last 20 years, and today LTx is considered 
to be a standard care for children and adolescents with terminal liver failure, 
metabolic disease, or malignancy, with a five-year patient survival rate varying 
from 70% to 85% (Kayler et al. 2002, Diem et al. 2003). The number of children 
living with a graft is on the rise, and complications independent of graft func-
tion are of increasing relevance to the long-term outcome of these patients. 
These include psychomotoric and cognitive development, kidney function, and 
growth and orthopedic problems in these patients (Adeback et al. 2003, Qvist 
et al. 2003, Campbell et al. 2006, Helenius et al. 2006a, 2006b). Determinants 
of LTx bone disease are not clearly defined. Pre-existing bone disease, life-long 
immunosuppressive medication, especially GCs, and disturbances in pubertal 
development may be important factors. We assessed bone health and its de-
terminants in 40 children and adolescents who had undergone LTx before the 
age of 16 years.
Okajima et al. (2003) showed in 30 consecutive children who underwent living-
related LTx that the LS aBMD Z-scores improved markedly after Tx, with the 
mean Z-score being + 0.16 after two years. None of these children had frac-
tures postoperatively, although three fractures were detected preoperatively. 
In contrast to the rapid bone loss reported in adults, no reduction in BMD oc-
curred in the early postoperative period in these patients (Okajima et al. 2003). 
Khan et al. (2006) reported cross-sectional bone health data on 15 young adults 
who had undergone LTx during childhood or adolescence. The mean time after 
LTx was 12 years. Four limb fractures were reported postoperatively in these 
patients, but VFx were not assessed. The mean BMD Z-score for the LS was -0.4 
and for the whole body -0.9; BMD values were statistically higher in patients 
on GCs at the time of the study (Khan et al. 2006).
VFx were present in 18% of our LTx patients. The fractures seemed to occur 
quite soon after LTx, especially in adolescent patients. The higher prevalence 
of VFx in recently transplanted patients suggests that the high GC doses used 
immediately after Tx may be more harmful than the cumulative dose and total 
duration of GC treatment. All of the VFx were asymptomatic, and the exact 
time of their occurrence remained unclear. Spontaneous remodeling after VFx 
occurs in early childhood, but usually not after the age of 13 years (Karlsson 
et al. 2003). Since BMD values significantly improved during the postoperative 
years, some recovery in vertebral morphology likely also occurred. The aBMD 
Z-scores were significantly lower in patients with VFx, in all measured sites. 
Almost all of the observed VFx were located in the thoracic region and only 
11% in the lumbar region. In adults, vertebral fractures in the LS are more 
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common. Gallacher et al. (2007) reported that 22% of the subjects had frac-
tures in the lumbar region and 21% in both the thoracic region and the LS. 
Therefore, the thoracic spine should be carefully evaluated for the presence of 
fractures, and standard spinal radiographs are often needed because thoracic 
vertebrae do not clearly visualize in the images produced by DXA (Mäyränpää 
et al. 2007).  
In the retrospective analysis, we found that the LS BMD was significantly re-
duced at the time of LTx, but gradually improved to a peak value of -0.5 at 
seven years postoperatively. These findings are in line with previous studies. 
However, the median BMD remained subnormal and at a lower level than ear-
lier reported in children (Okajima et al. 2003). Bone loss after LTx is greatest 
during the first 3-6 months postoperatively, when the GC doses are highest; this 
has been confirmed by bone histomorphometry (Bjoro et al. 2003, Guichelaar 
et al. 2004, Guichelaar et al. 2006).
The cross-sectional analysis in which the BMD values were corrected for bone 
age showed that more than half of our patients had LS Z-score ≤ -1.0 and 15% 
had ≤ -2.0, indicating that low BMD values are common in pediatric LTx recipi-
ents. The 19 patients (48%) transplanted as infants had higher aBMD values 
for the LS, hip, and whole body than those who were operated on later. The 
results suggest that low-dose GC exposure, even over several years, is usually 
well tolerated and does not necessarily translate into severe skeletal morbidity 
in children. The six patients with LS aBMD Z-score ≤ -2.0 were all transplanted 
at an older age (14.1 vs. 2.0 years, p = 0.002). 
Complete data on BMD development during pubertal years was available for 
10 of our subjects. In eight patients (80%), the aBMD Z-score decreased by ≥ 0.7 
during puberty, remaining significantly subnormal (mean LS Z-score -1.9) at the 
end of puberty in all of them. However, the median height Z-score remained 
stable during puberty signifying normal timing of the pubertal growth spurt. 
In healthy children, the most rapid increase in aBMD occurs during puberty in 
both genders, at 11-13 years in girls and at 13-17 years in boys (Bonjour et al. 
1991). Individual sensitivity to GCs is a recognized modifying factor and the pa-
tient’s age may also play a role, as pubertal patients seemed to be more prone 
to skeletal complications. Even small doses of GCs might interfere with normal 
bone mass accrual during the critical time of bone mass gain by  negatively in-
fluencing the synthesis and action of gonadotrophins and sex steroids (Canalis 
and Giustina 2001). 
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6.4 Bone health in children and adolescents after renal 
transplantation
The frequency of low BMD values in children is dependent on the interpreta-
tion of results (Leonard 2005). In general, correction of BMD values for statu-
ral height or weight (instead of chronological age) reduces the frequency of 
subnormal values in children and adolescents (Klaus et al. 1998, Sanchez et al. 
1998 Saland et al. 2001). Children with chronic renal failure often have short 
stature and linear growth is impaired even after successful RTx. Therefore, this 
correction of BMD values is important (Offner et al. 1999, Ninik et al. 2002, 
Nissel et al. 2004). In our patients, bone age was delayed by more than one 
year in almost half of the patients. We found thus it important to correct the 
BMD values for bone age to avoid overestimation of the BMD reductions in 
the cohort.
We evaluated bone health and the prevalence of low BMD, fractures, and lon-
gitudinal changes in BMD in a cohort of 106 pediatric RTx patiens. The overall 
bone health in our pediatric RTx patients was satisfactory. The bone-age-cor-
rected BMD values were normal in most RTx patients, and the Z-score for LS, 
hip, and whole body was below –2.0 in only 4-6% of patients. Only one previ-
ous study has been published in which correction for bone age was used in 19 
renal transplant children. In that study, the BMD Z-score for LS was below -2.0 
in 63% vs. 26% and for femoral neck in 56% vs. 17% of  patients when the 
values were adjusted for patient’s chronological age or bone age, respectively 
(Goksen et al. 2005). 
In Finland, the proportion of patients who have undergone RTx as infants is 
higher than in any other transplantation center in the world. This is due to the 
exceptionally high prevalence of nephrotic syndrome of the Finnish type, a 
disease belonging to the Finnish disease heritage. We therefore compared the 
BMD results of those transplanted before the age of two years with the others. 
Importantly, we showed that the aBMD Z-scores of children and adolescents 
transplanted as infants did not differ from those who underwent Tx at an older 
age. The exposure to the low-dose alternate- day GC regimen was longer in 
these subjects, but this treatment seemed to be well tolerated. The time on 
dialysis did not differ in these patient groups. 
Low BMD values for both the LS and hip were significantly more common in 
adolescent girls than in younger girls or adolescent boys. This is unlikely due 
to delayed pubertal development since the mean age of menarche was nor-
mal (12.9 years) also in the females who were over 15 years at the time of this 
study. In adolescent females, even small doses of GCs have been speculated 
to interfere with bone mass accrual by negatively influencing the synthesis 
and action of gonadotrophins and sex steroids (Canalis and Giustina 2001). 
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According to these observations, careful bone health evaluation is warranted, 
especially during puberty. 
In Studies I and III on children with JIA and LTx, we failed to find a correlation 
between total GC exposure and BMD values; instead of the overall cumula-
tive GC dose, skeletal health may be determined by more recent GC exposure. 
Therefore, only GC doses used during the three preceding years were included 
in Study IV. Logistic regression analysis confirmed that the cumulative MP dose 
during the preceding three years was a significant independent risk factor for 
low BMD (OR 5.72;1.52 -21.56, p = 0.008). Patients with a higher MP dose had 
a shorter time since RTx and were exposed to acute rejections, which mostly 
occur postoperatively during the first six months. Individual sensitivity to GC is 
a recognized modifying factor, and the patient’s age may also play a role, as 
pubertal girls were more prone to skeletal complications (Chesney et al. 1984, 
Cooper 2004). 
High-turnover bone disease associating with high serum PTH levels is the most 
common form of renal osteodystrophy in children on dialysis (Wesseling et al. 
2008). Usually CKD-bone and mineral disease improves after RTx. However, in 
some patients hyperparathyroidism may persist for years. During dialysis treat-
ment, oversuppression of PTH should be avoided to prevent development of 
adynamic bone disease (Wesseling et al. 2008). 
The prevalence of VFx in our cohort was 8%, which is high considering the 
satisfactory BMD values. Most of the fractures were asymptomatic and would 
not have been detected without specific screening. Some of the patients trans-
planted as infants might have sustained VFx, but because of the suggested 
tendency for spontaneous recovery of VFx, during childhood growth (Karlsson 
et al. 2003) these fractures were no longer visible at the time of this study. 




6.5 Juvenile idiopathic arthritis or solid organ transplan-
tation and vitamin D 
Low vitamin D values were found in all of our patient groups exposed to GC 
treatment. The optimal vitamin D level for risk groups to prevent secondary os-
teoporosis is speculated to be about 80 nmol/L and only one-fourth of our pa-
tients achieved this level (Bischoff-Ferrari et al. 2006). For healthy children and 
adolescents vitamin D level of  > 50 nmol/L is considered as indicative of vita-
min D sufficiency (Misra et al. 2008). In contrast to previous studies no seasonal 
variation of vitamin D values was found in our patients. The use of sunscreens, 
highly recommended for early prevention of skin cancer in children after Tx, 
may partly explain this. Also, vitamin D substitution may mask this variation.
Little is known about calcium and vitamin D in JIA. In a study of 13 JIA patients, 
the mean baseline aBMD Z-score for the LS was -2.8 ± 0.5, and this increased 
with vitamin D substitution to -2.3 ± 0.5 after six months and to -2.4 ± 0.4 after 
one year (Reed et al. 1991). In most of our patients, the vitamin D values were 
suboptimal, and only two (3%) of the subjects reached the level of 80 nmol/L. 
Only one-third of the patients were on vitamin D substitution. It is important 
to ensure sufficient intake of these nutrients, as vitamin D deficiency is highly 
prevalent in healthy children and adolescents, especially in the northern lati-
tudes (Lehtonen-Veromaa et al. 2002, Välimäki et al. 2004).
Eleven (28%) of our LTx patients had vitamin D values ≥ 80 nmol/L, while five 
subjects (13%) had level below 37 nmol/L. Most of the patients were on vita-
min D and calcium substitution. However, based on these results, the dosing 
may have been inadequate for attaining optimal vitamin D levels. None of the 
patients had PTH values greater than 100 ng/L.
Plasma PTH above 100 ng/L was an independent predictor for reduced LS BMD 
in patients with RTx. Cohen et al. (2005) reported in nine adult survivors of 
pediatric HTx that elevated PTH may contribute to osteoporosis. In another 
study, all 58 adult RTx patients had elevated PTH values despite good renal 
function, and higher PTH values were measured in those with osteoporosis 
and high bone turnover (Cruz et al. 2002). According to the European pediatric 
guidelines, the PTH levels should be within the normal range in patients not on 
dialysis (Klaus et al. 2006). Vitamin D deficiency may cause PTH elevation also in 
patients with good graft function, and thus should be avoided.
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6.6 Limitations of the study
Several limitations, mainly related to the study populations and applied meth-
odology, were identified during this study. While the studies on fracture epide-
miology in the transplant population and on bone health determinants in the 
RTx patients included a large number of patients, the studies on JIA and LTx 
patients were insufficiently powered to assess independent predictors of bone 
health. Furthermore, the cohort of JIA also included patients with relatively 
mild disease and may thus have failed to show the spectrum of skeletal com-
plications in patients with more severe presentation. The number of patients 
with JIA treated with TNF-α antagonists was small, and the potential benefits 
of these medications for bone health could not be evaluated. However, the 
transplant cohorts were larger than in previous pediatric studies and included 
practically all pediatric LTx and RTx patients in the country. 
We did not have control groups for most of the cohorts. In the epidemiologi-
cal study, the control group consisted of patients aged 0-30 years, who had 
sustained a fracture during 2001 and who were treated for the fracture at pri-
mary healthcare centers or university hospitals in the city of Helsinki. Possibly, 
the true fracture rate in the control population may have been higher, as some 
milder fractures might have been treated in private clinics, and thus were not 
included in the register. Furthermore, the controls were not screened for VFx, 
and therefore the observed VFx rate may be an underestimation. 
DXA has many limitations in pediatric use. Usually, the child must be at least 
four years of age to be able to stay still during the measurements. The asso-
ciation between low BMD and fractures is less established in children than in 
adults. DXA is based on two-dimensional assessment of three-dimensional skel-
etal structures and measures only aBMD, instead of volumetric BMD. The refer-
ence ranges of DXA are based on healthy children, and subjects with short stat-
ure or delayed skeletal maturity may have falsely low BMD values. Correction 
of the BMD for bone age and/or height is essential to avoid misinterpretation 
of the results. In the cross-sectional studies, we adjusted all BMD values with 
bone age. However, in the longitudinal analyses, no bone age films were avail-
able and only unadjusted values were used. 
New methods for more accurate bone quantitation have been developed. 
Quantitative computed tomography measures true volumetric bone density, 
which is not size-dependent, and provides separate measurements for trabecu-
lar and cortical BMD. The radiation dose is, however, much higher than in DXA, 
limiting its use in children and adolescents. Peripheral quantitative computed 
tomography is more useful for pediatric purposes, and the sites used in the 
measurements include the distal radius, tibia, and femur. This method allows in-
formation to be obtained for both trabecular and cortical bone. Unfortunately, 
no reference values exist for children. 
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No follow-up data of vitamin D measurements in our patients were available, 
and therefore vitamin D status at the onset of JIA and at the time of Tx or frac-
ture remains unknown.
6.7 Future considerations
Many of the research questions presented here would be ideally investigated 
in prospective study settings with larger patient cohorts. A prospective study 
on patients with newly diagnosed JIA would be optimal to evaluate BMD de-
velopment and the incidence of fractures. This study setting, with regular BMD 
assessment with DXA and peripheral computed tomography would allow more 
reliable assessment of the potential risk factors and the impact of TNF-α an-
tagonists on bone health. In transplantation patients, the role of GCs in bone 
mass development can be evaluated accurately only if steroid-free protocols 
are also widely used in children and adolescents. 
This study described the spectrum of bone disease in patient cohorts and iden-
tified potential risk factors for low BMD and fractures. However, elucidation of 
optimal preventive measures and the role of bisphosphonates in the treatment 




Studies I-IV evaluated bone health in patients with JIA or a history of solid 
organ transplantation.
The main conclusions were the following:
1) Median BMD values were subnormal in all patient cohorts. The values were 
highest in patients with JIA and lowest in LTx patients. In the transplant pa-
tients, BMD was lowest during the immediate posttransplantation years, in-
creasing subnormally during puberty. Delayed skeletal maturation was com-
mon in all patient groups, and therefore, correcting BMD results for bone age
was essential.
2) Vertebral fractures were common in all patient groups and were mostly 
asymptomatic. Their diagnosis is thus dependent on active screening by spinal 
imaging. Vertebral fractures were most common in LTx patients, with a preva-
lence of almost 20%.
3) The total cumulative weight-adjusted GC did not correlate with BMD or frac-
tures in patients with JIA or LTx. By contrast, the cumulative weight-adjusted 
dose of GC during the three preceding years was a significant independent risk 
factor for low LS BMD in RTx patients.
4) Vitamin D deficiency was common, and only 3% of  patients with JIA and 
about 25% of  patients with LTx or RTx were considered to have adequate se-
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